Formulation and Evaluation of Sustained Release Matrix Tablets of Venlafaxine Hydrochloride by Archana, M
 
 
 
FORMULATION AND EVALUATION OF SUSTAINED 
RELEASE MATRIX TABLETS OF VENLAFAXINE 
HYDROCHLORIDE  
 A Dissertation Submitted to  
The Tamil Nadu Dr. M.G.R. Medical University 
Chennai - 600 032 
In partial fulfillment for the award of Degree of 
MASTER OF PHARMACY 
(Pharmaceutics) 
Submitted by 
ARCHANA.M 
Register No. 26116001 
Under the Guidance of 
Dr. S. SHANMUGAM, M. Pharm., Ph.D. 
 Professor 
Department of Pharmaceutics 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY 
(Accredited By “NAAC” with CGPA of 2.74 on a Four point Scale at “B” Grade) 
MELMARUVATHUR - 603 319 
APRIL 2013 
 
 
 
 
                                             CERTIFICATE 
 
           This is to certify that the dissertation entitled
 “
FORMULATION AND   
EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF 
VENLAFAXINE HYDROCHLORIDE
”
 submitted to The Tamil Nadu Dr. M.G.R. 
Medical University in partial fulfillment for the award of the Degree of the Master of 
Pharmacy (Pharmaceutics) was carried out by ARCHANA.M (Register No. 26116001) 
in the Department of Pharmaceutics under my direct guidance and supervision during 
the academic year 2012-2013. 
 
 
 
 
 
 
 
 
 
Place: Melmaruvathur                             Dr. S. SHANMUGAM, M. Pharm., Ph.D., 
  Date:                                                          Professor,     
                                           Department of Pharmaceutics, 
                                                                  Adhiparasakthi College of Pharmacy,   
                                                                  Melmaruvathur - 603 319.    
 
 
 
 
                                                          
                                                      CERTIFICATE 
 
 This is to certify that the dissertation entitled 
“
FORMULATION AND 
EVALUATION OF  SUSTAINED RELEASE MATRIX TABLETS OF 
VENLAFAXINE HYDROCHLORIDE
”
 the bonafide research work carried out by 
ARCHANA.M (Register No. 26116001) in the Department of Pharmaceutics, 
Adhiparasakthi College of Pharmacy, Melmaruvathur which is affiliated to The Tamil- 
Nadu Dr. M.G.R. Medical University under the guidance of Dr. S. SHANMUGAM,   
M. Pharm., Ph.D., Professor, Department of Pharmaceutics, Adhiparasakthi College of 
Pharmacy, Melmaruvathur. 
 
 
 
 
 
 
 
 
 
Place: Melmaruvathur                Prof. Dr. T. VETRICHELVAN, M. Pharm., Ph.D., 
  Date:                                             Principal, 
                                                    Adhiparasakthi College of Pharmacy, 
                                                    Melmaruvathur - 603 319.
 
 
 
 
 
 Dedicated to  
  My beloved  
Parents & Friends… 
 
 
 
 
                                   ACKNOWLEDGEMENT 
 
            First and foremost, I wish to express my deep sense of gratitude to his 
Holiness ARULTHIRU AMMA for his ever growing Blessings in each step of the 
study. 
 With great respect and honor, I extend my thanks to our Vice-President 
THIRUMATHI LAKSHMI BANGARU ADIGALAR, ACMEC trust, 
Melmaruvathur for her excellence in providing skillful and compassionate spirit of 
unstinted support to our department for carrying out dissertation entitled 
“
FORMULATION AND EVALUATION OF  SUSTAINED RELEASE   
MATRIX TABLETS OF VENLAFAXINE HYDROCHLORIDE
”
. 
 I got inward bound and brainwave to endure experimental investigations in 
novel drug delivery systems, to this extent. I concede my in most special gratitude and 
thanks to Dr. S. SHANMUGAM, M. Pharm., Ph.D., Professor, Department of 
Pharmaceutics, Adhiparasakthi College of Pharmacy, for the active guidance, 
innovative ideas, and creative works, infinite helps, indulgent and enthusiastic 
guidance, valuable suggestions, a source of inspiration where the real treasure of my 
work. 
 I owe my sincere thanks with bounteous pleasure to                                   
Prof. Dr. T. VETRICHELVAN, M. Pharm., Ph.D., Principal, Adhiparasakthi 
College of Pharmacy, without his encouragement and supervision it would have been 
absolutely impossible to bring out the work in this manner. 
           I have great pleasure in express my sincere heartfelt thanks to Prof. K. 
SUNDARAMOORTHY, B.Sc., M. Pharm., Mr. T. AYYAPPAN, M. Pharm., 
 
 
 
Assistant Professor, Mr. A. UMAR FARUKSHA, M. Pharm., Lecturer, 
Department of Pharmaceutics. Mr. K. ANANDAKUMAR, M. Pharm., Assistant 
Professor, Department of Pharmaceutical Analysis, for encouragement and support 
for the successful completion of this work. 
My sincere thanks to our lab technicians Mrs. S. KARPAGAVALLI, D. 
Pharm., B.B.A., and Mr. M. GOMATHI SHANKAR, D. Pharm., for their kind 
help throughout this work. 
           I am indeed very much thankful to the librarian Mr. M. SURESH, M.L.I.S., 
for providing all reference books for the completion of this project. 
           I am thankful to all my class friends and seniors for their support and 
suggestion during my work. 
           Finally yet importantly, I gratefully forward my affectionate thanks to my 
family members for their frequent prayers, which has sustained me a lot in the 
successful completion of my project work.  
 
                         
                   
 
 
                                                                                                                               ARCHANA.M 
 
 
 
 
 
       CONTENTS 
CHAPTER TITLES PAGE 
No. 
1. INTRODUCTION 1 
1.1 Oral drug delivery system 2 
1.2 Drawbacks of conventional dosage forms 3 
1.3 Sustained release drug delivery system 4 
1.4 Oral controlled and sustained release systems 14 
1.5 Matrix tablets 22 
1.6 Methods  used in tablet manufacturing 29 
1.7 Depression 36 
2. NEED AND OBJECTIVES 43 
3. PLAN OF WORK 46 
4. LITERATURE REVIEW 49 
5. DRUG AND EXCIPIENTS PROFILE 61 
5.1 Drug profile 62 
5.2 Excipients profile 66 
6. MATERIALS AND EQUIPMENTS 78 
6.1 Materials used 79 
6.2 Equipments used 80 
   
 
  
 
 
 
CHAPTER TITLES PAGE 
No. 
7. EXPERIMENTAL WORK  81 
7.1 Preformulation study 82 
7.2 Preparation of SR matrix tablets 90 
7.3 
Evaluation of  Venlafaxine Hydrochloride sustained 
release  matrix tablets 
90 
7.4 Stability study 95 
8. RESULTS AND DISCUSSION 96 
8.1 Preformulation parameters 97 
8.2 Evaluation of granules  111 
8.3 Evaluation of sustained release matrix tablets 112 
8.4 Stability study 134 
9. SUMMARY AND CONCLUSION 139 
10. FUTURE PROSPECTS 142 
11. BIBLIOGRAPHY 144 
 
 
 
 
 
 
 
  
 
 
 
LIST OF TABLES 
TABLE 
No. 
CONTENTS 
PAGE 
No. 
6.1 List of materials with source 79 
6.2 List of equipments with model/make 80 
7.1 
Composition of  Venlafaxine Hydrochloride SR matrix  
tablet 
87 
7.2 Standard values of angle of repose 88 
7.3 Standard values of Carr‟s index 89 
7.4 
Specifications of % weight variation allowed in tablets as 
per Indian Pharmacopoeia 
92 
7.5 Diffusion exponent and solute release mechanism 94 
8.1 
Characteristic frequencies in FTIR spectrum of 
Venlafaxine Hydrochloride 
98 
8.2 
Solubility of Venlafaxine Hydrochloride in different 
solvents 
99 
8.3 Percentage loss on drying for Venlafaxine Hydrochloride 99 
8.4 
Concentration and absorbance of Venlafaxine 
Hydrochloride in 0.1N HCl 
102 
8.5 Calibration  parameter values in 0.1N HCl 102 
8.6 
Concentration and absorbance of Venlafaxine 
Hydrochloride in pH 6.8 phosphate buffer  
103 
8.7 Calibration  parameter values in pH 6.8 phosphate buffer 104 
8.8 
Percentage purity of Venlafaxine Hydrochloride in pure 
drug  
104 
 
 
 
 
TABLE 
No. 
CONTENTS 
PAGE 
No. 
8.9 
FTIR peaks observed for Venlafaxine Hydrochloride 
with different polymers used in formulations 
107 
8.10 
DSC thermogram parameters of Venlafaxine 
Hydrochloride with carnauba wax 
110 
8.11 Flow characteristics of granules 111 
8.12 
Physicochemical parameters of Venlafaxine 
Hydrochloride matrix tablet 
113 
8.13 Dissolution profile of formulation VF1 115 
8.14 Dissolution profile of formulation VF2 116 
8.15 Dissolution profile of formulation VF3 117 
8.16 Dissolution profile of formulation VF4 118 
8.17 Dissolution profile of formulation VF5 119 
8.18 Dissolution profile of formulation VF6 120 
8.19 Dissolution profile of formulation VF7 121 
8.20 Dissolution profile of formulation VF8 122 
8.21 Dissolution profile of formulation VF9 123 
8.22 
Different kinetic models  for Venlafaxine Hydrochloride 
matrix tablets (VF1 to VF9) 
129 
8.23 Stability studies of  best  formulation (VF3) 135 
 
 
 
 
LIST OF FIGURES 
FIGURE 
No. 
CONTENTS 
PAGE 
No. 
1.1 
Plasma concentration vs time profile from conventional 
dosage and doses of sustained and controlled delivery 
formulations. 
5 
1.2 
Typical relationship between drug activity and partition 
coefficient, K, generally known as Hansch correlation. 10 
1.3 
Schematic representation of reservoir diffusion device Cm 
(o), and Cm (d) represent concentration of drug inside 
surfaces of membrane and C (o) & C(d) represents 
concentration in adjacent  regions. 
17 
1.4 
Diagrammatic representation of slab configuration of 
reservoir diffusion system. 18 
1.5 
Plot showing approach to steady state for reservoir device 
that has been stored for an extended period (the burst effect 
curve) and for device that has been freshly made (the time 
lag curve). 
19 
1.6 
Matrix diffusion system before release & after partial drug 
release. 20 
1.7 
Schematic representation of the physical model used for a 
planer slab matrix diffusion device. 21 
1.8 Manufacturing Steps For Direct Compression. 
33 
8.1 FTIR spectrum of Venlafaxine Hydrochloride. 
97 
8.2 λ max observed for Venlafaxine Hydrochloride in 0.1N HCl. 100 
8.3 
λ max observed for Venlafaxine Hydrochloride in pH 6.8 
phosphate buffer. 
101 
 
 
 
 
FIGURE 
No. 
CONTENTS 
PAGE 
No. 
8.4 
Calibration curve of  Venlafaxine Hydrochloride in 0.1 N 
HCl. 
102 
8.5 
Calibration curve of  Venlafaxine Hydrochloride in pH 6.8 
phosphate buffer 
103 
8.6 
FTIR spectrum of  Venlafaxine Hydrochloride with 
Carnauba wax 
105 
8.7 
FTIR spectrum of  Venlafaxine Hydrochloride with Cetyl 
alcohol 
105 
8.8 
FTIR Spectrum of  Venlafaxine Hydrochloride with Stearic 
acid 
106 
8.9 DSC thermal analysis of  Venlafaxine Hydrochloride      108 
8.10 
DSC thermal analysis of  Venlafaxine Hydrochloride with 
Carnauba wax 
109 
8.11 In vitro drug release profile of formulation VF1 115 
8.12 In vitro drug release profile of formulation VF2 116 
8.13 In vitro drug release profile of formulation VF3 117 
8.14 In vitro drug release profile of formulation VF4 118 
8.15 In vitro drug release profile of formulation VF5 119 
 
 
 
FIGURE 
No. 
CONTENTS 
PAGE 
No. 
8.16 In vitro drug release profile of formulation VF6 120 
8.17 In vitro drug release profile of formulation VF7 121 
8.18 In vitro drug release profile of formulation VF8 122 
8.19 In vitro drug release profile of formulation VF9 123 
8.20 
In vitro drug release profile of formulations containing 
Carnauba wax polymer 
124 
8.21 
In vitro drug release profile of formulations containing Cetyl 
alcohol polymer 
124 
8.22 
In vitro drug release profile of formulations containing 
Stearic acid polymer 
125 
8.23 
In vitro drug release profile for different polymer at 15% 
concentration 
125 
8.24 
In vitro drug release profile for different polymer at 30% 
concentration 
126 
8.25 
In vitro drug release profile for different polymer at 45% 
concentration 
126 
8.26 In vitro drug release profile of VF1 to VF9 127 
8.27 Best fit model (Peppas) of formulation VF1 130 
8.28 Best fit model (Peppas) of formulation VF2 130 
8.29 Best fit model (Peppas) of formulation VF3 131 
8.30 Best fit model (Peppas) of formulation VF4 131 
8.31 Best fit model (Peppas) of formulation VF5 132 
 
 
 
 
 
FIGURE 
No. 
CONTENTS 
PAGE 
No. 
8.32 Best fit model (Peppas) of formulation VF6 132 
8.33 Best fit model (Peppas) of formulation VF7 133 
8.34 Best fit model (Peppas) of formulation VF8 133 
8.35 Best fit model (Peppas) of formulation VF9 134 
8.36 
Comparison for hardness  before and after stability studies of 
best formulation VF3 135 
8.37 
Comparison for friability before and after stability studies of 
best formulation VF3 136 
8.38 
Comparison for drug content before and after stability studies 
of best formulationVF3 136 
8.39 
Comparison for in vitro drug release profile before and after 
stability studies of best formulation VF3 137 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 ABBREVIATION AND MEANING  
% Percentage 
%DE Percentage dissolution efficiency 
µ Micron 
µg/ml Microgram per milliliter 
0
C Degree Celsius 
Cm
-1 
Centimeter inverse 
Cmax Peak plasma concentration 
BP British Pharmacopoeia 
DSC Differential scanning calorimetry 
e.g. Example 
Edn Edition 
F Formulation 
F/C Film coated 
FTIR Fourier transform infrared spectroscopy 
g/ml gram per milliliter 
GIT Gastro intestinal tract 
HCl Hydrochloric acid 
 
 
 
 
 
Hrs Hours 
ICH 
International conference on 
harmonization 
IP Indian pharmacopoeia 
Kg/cm
2
 kilogram per centimeter square 
LBD Loose bulk density 
MDT Mean dissolution time 
Mg Milligram 
Ml Millilitre 
ml/min millilitre per minute 
Mm Millimeter 
N Normality 
NaOH Sodium hydroxide 
NF National formulary 
Nm Nanometer 
º Degree 
pH Negative logarithm of hydrogen ion 
pKa Dissociation constant 
 
 
 
 
 
 
  
Qs Quantity sufficient 
RH Relative humidity 
Rpm Revolution per minute 
S.No. Serial number 
SD Standard deviation 
SR Sustained release 
t1/2 Biological half life 
TBD Tapped bulk density 
Tmax Time of peak concentration 
USP United states pharmacopoeia 
UV Ultraviolet 
w/w weight per weight 
λmax Absorption maximum
 
 
 
 
 
 
  
 
 
 
 
 
 
 
INTRODUCTION 
       
 
 
 
Venlafaxine Sustained Release Matrix Tablets                  INTRODUCTION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  2 
 
   1.INTRODUCTION 
 
1.1. Oral drug delivery system:     (Banker G.S. and Rhodes C.T., 2009; Chein Y.W., 
2009; http://www.pharmainfo.net)    
Oral route has been the commonly adopted and most convenient route for the 
drug delivery. Oral route of administration has been received more attention in the 
pharmaceutical field, because of the more flexibility in the designing of dosage form 
than drug delivery design for other routes. The oral drug delivery depends on various 
factors such as type of delivery system, the disease being treated, the patient, the 
length of the therapy and the properties of the drug. Most of the oral controlled drug 
delivery systems (OCDDS) relay on diffusion, dissolution, or combination of both 
mechanisms, to release the drug in a controlled manner to the gastro intestinal tract 
(GIT). The physico-chemical properties include crystal nature, solubility, partition 
coefficient, intrinsic dissolution, etc. dosage form characteristics are controlled and 
optimized with respect to the physico-chemical properties of the drug and relevant GI 
environmental factors. Other factors need to be considered are diseased state, the 
patient compliance & length of therapy. The goal of targeted oral drug delivery 
systems is to achieve better therapeutic success compared to conventional dosage 
form of the same drug. This could be achieved by improving the pharmacokinetic 
profile, patient convenience and compliance in therapy. 
Oral route of drug delivery has been known for decades as the most to a wide 
extent used route of administration among all the routes that have been travel through 
to learn about it the systemic delivery of drugs via various pharmaceutical 
manufactured products of various dosage forms.  
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Oral route of administration has been used as either conventional or novel 
drug delivery system. There are many merits are there for this, not the least of which 
would include willingness to accept by the patient and facility of administration. 
Types of sustained release system employed for oral route of administration include 
virtually every at the present time now the theoretical mechanism for such 
application. This is because the manufacturing of dosage form is more flexibility, 
since constraint, such as sterility problem and potential damage at the site of 
administration are minimized. Because of this, it is easy to development of different 
types of dosage forms by customary those developed for oral route of administration 
as initial examples. 
    Regarding orally administered drugs, targeting is not a primary concern, and it 
is usually done on purpose for active component to permeate to the blood circulation 
and permeation through the other body tissue (the obvious exception being 
medication intended for local gastrointestinal tissue treatment). For this justification, 
most system employed the sustained release variety. 
Concentration of drug level it will increasing the rate absorption region and 
also, increase circulating blood levels, which in turn to raise to greater concentration 
of active content at the site of action. 
 
1.2. Drawbacks of Conventional Dosage Forms:      (Brahmankar D.M. and Jaiswal 
S.B., 2009; Shalin A. Modi, et al., 2011) 
1. Poor patient compliance, increased chances of missing the dose of a drug 
with short half-life for which frequent administration is necessary. 
2. The unavoidable fluctuations of drug concentration may lead to under 
medication or over medication. 
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3. A typical peak-valley plasma concentration time profile is obtained which 
makes attainment of steady-state condition difficult. 
4. The fluctuations in drug levels may lead to precipitation of adverse effects 
especially of a drug with small Therapeutic Index (TI) whenever over medication 
occur. 
 
1.3. Sustained release drug delivery system:     (Banker G.S. and Rhodes C.T., 
2009; http://www.pharmainfo.net) 
Over past 30 year as the expanse and complication involved in marketing new 
drug entities have increased, with concomitant recognition of the therapeutic 
advantages of controlled drug delivery, greater attention has been focused on 
development of sustained or controlled release drug delivery systems. There are 
several reasons for the attractiveness of these dosage forms. It is generally recognized 
that for many disease states, a substantial number of therapeutically effective 
compounds already exist.  
The effectiveness of these drugs, however, is often limited by side effects or 
the necessity to administer the compound in a clinical setting, the goal in designing 
sustained or controlled delivery system is to reduce the frequency of dosing or to 
increase effectiveness of the drug by localization at the site of action, reducing the 
dose required, or providing uniform drug delivery. Sustained release constitutes any 
dosage form that provides medication over and extended time. Controlled release, 
however, denotes that the system is able to provide some actual therapeutic control, 
whether this is of a temporal nature, spatial nature or both.  
This correctly suggests that there are sustain release system that cannot be 
considered controlled release system. In general, the goal of a sustained release 
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dosage form is to maintain therapeutic blood or tissue levels of drug for an extended 
period this is usually accomplished by attempting to obtain zero-order release from 
the dosage form; zero-order release constitutes drug release from the dosage form. 
Sustained release systems generally do not attain this type of release and provides 
drug is a slow first order fashion. In recent year sustained release dosage forms 
continue to draw attention in the search for improved patient compliance and 
decreased incidence of adverse drug reactions. Sustained release technology is 
relatively cow field and as a consequence, research in the field has been extremely 
fertile and has produced many discoveries.  
Sustained release, sustained action, prolonged action controlled release, 
extended action, timed release, depot and repository dosage forms are terms used to 
identify drug delivery system that are designed to achieve or prolonged therapeutic 
effect by continuously releasing medication over an extended period of time after 
administration of a single dose. 
 
Figure 1.1: Plasma concentration versus time profile from conventional dosage and     
                   doses of sustained and controlled delivery formulation. 
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          Systems that are designed as prolonged release can also be considered as 
attempts at achieving sustained-release delivery. Repeat action tablets are an 
alternative method of sustained release in which multiple doses of drug are contained 
within a dosage form, and each dosage is related to a periodic interval. Delayed 
release systems, in contrast may not be sustaining, science often function of these 
dosage forms is to maintain the drug within the dosage form for some time before 
release. Commonly the release rate of drug is not altered and does not result in 
sustained delivery once drug release has begun.  
Successful fabrication of sustained release products is usually difficult & and 
involves consideration of physicochemical properties of drug, pharmacokinetic 
behavior of drug, route of administration, disease state to be treated and, most 
importantly, placement of the drug in dosage form total will provide the desired 
temporal and spatial delivery pattern for the drug.  
The slow first order release obtained by a sustained release pre parathion is 
generally achieved by the release of the drug from a dosage form. In some cases in 
some cases, this achieved by making slow the release of drug from a dosage form. In 
some cases, this is accomplished by a continuous release process.  
 
1.3.1. Potential advantages of Sustained release drug delivery system:  
(http://www.pharma info.net) 
1. Patient compliance due to reduction in the frequency of designing. 
2. Employ minimum drug. 
3. Minimize or eliminates local and systemic side effects. 
4. Obtain less potentiating or deduction in drug activity with chronic use. 
5. Minimize drug accumulation with chromic dosing. 
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6. Improves efficacy in treatment. 
7. Cure or control confirm more promptly. 
8. Improve control of condition i.e. reduce fluctuation in drug level. 
9. Improve bioavailability of same drugs. 
10. Make use of special effects, e.g. sustained release aspect for morning relief of    
arthritis by dosing before bedtime. 
 
1.3.2. Disadvantages of Sustained release drug delivery system:    (http: //www. 
pharmainfo.net)  
1.   They are costly. 
2.   Unpredictable and often poor in-vitro in-vivo correlations, dose dumping,        
      Reduced potential for dosage adjustment and increased potential first pass    
      clearance. 
3.   Poor systemic availability in general. 
4. Effective drug release period is influenced and limited by GI residence time. 
 
1.3.3. Rationale of sustained release drug delivery system:     (Ansel H.C., 2009; 
Vyas S.P and Khar R.K., 2002) 
 To optimizing the factor such as pharmacokinetic, pharmacodynamic and 
biopharmaceutical these are the rationale of sustained release dosage form, these 
properties of active ingredient in such a type its maximum reducing the adverse effect 
and controlling disease growth condition in short time period by loading less quantity 
of drug, when we are administered in the suitable route. Many drugs are longer action 
because half life and only need for once day dosing so these type of drug not for 
sustained or controlled release tablet to give therapeutic effect in blood and this nature 
of drug we can be manufacturing in immediate release tablet as like conventional 
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tablet. However, some drugs are not long action and need multiple daily dosing to 
obtain the therapeutic results.  
 Multiple daily dosing is inconvenient for the patient, chance of missed doses, 
made up doses and non compliance with the regimen. When the conventional tablet 
which may causes variation of plasma level peaks and valley associated with the 
using of each dose. However, when a dose should not be administering such a manner 
because the obtaining  result like peaks and valley give the less action of therapy. For 
example if a dosage form is administered short time interval, minimum toxic 
concentration of drug may be reached, with toxic side effect can occur. If doses are 
missed or forgetted, the administered drug goes to sub therapeutic levels on those 
below the minimum effective concentration (MEC) may result, so there is no use to 
the patient. 
 
1.3.4. Designing sustained-release drug delivery system:      (Shalin A. Modi, et al., 
2011) 
 Most of the orally administered drugs, targeting is not a primary concern and it 
is usually intended for drugs to penetrate to the general circulation and perfuse to 
other body tissues. For this reason, most systems employed are of the sustained 
release variety. It is assumed that increasing concentration at the absorption site will 
increase circulating blood levels, which in turn, promotes greater concentration of 
drug at the site of action. If toxicity is not an issue, therapeutic levels can thus be 
extended. In essence, drug delivery by these systems usually depends on release from 
some type of dosage form, permeation through biological milieu and absorption 
through an epithelial membrane to the blood. There are a variety of both 
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physicochemical and biological factors that come into play in the design of such 
system.  
 
1.3.5. Factors Affecting Sustained Release Dosage Forms:     (Chein Y.W., 2009; 
http://www.pharmainfo.net) 
1.3.5.1. Physicochemical properties of drug: 
a) Dose Size: 
If an oral product has a dose size greater that 0.5gm it is a poor candidate for 
sustained release system, Since addition of sustaining dose and  possibly the 
sustaining mechanism will, in most cases generates a substantial volume product that 
unacceptably large.  
b) Aqueous Solubility:  
Most of drugs are weak acids or bases, since the unchanged form of a drug 
preferentially permeates across lipid membranes drugs aqueous solubility will 
generally be decreased by conversion to an unchanged form for drugs with low water 
solubility will be difficult to incorporate into sustained release mechanism. The lower 
limit on solubility for such product has been reported 0.1mg/ml. drugs with great 
water solubility are equally difficult to incorporate in to sustained release system. pH 
dependent solubility, particularly in the physiological pH range, would be another 
problem because of the variation in pH throughout the GI tract and hence variation in 
dissolution rate.  
c) Partition Coefficient: 
Partition coefficient is generally defined as the fraction of drug in an oil phase 
to that of an adjacent aqueous phase. Accordingly compounds with relatively high 
partition coefficient are predominantly lipid soluble and consequently have very law 
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aqueous solubility. Compounds with very law partition coefficients will have 
difficulty in penetrating membranes resulting poor bioavailability.  
 
Figure 1.2: Typical relationship between drug activity and partition coefficient K. 
d) Dissociation constant (pka):  
The  relationship between dissociation constant of compound and absorptive 
environment. Presenting drug in an unchanged form is adventitious for drug 
permeation but solubility decrease as the drug is in unchanged form.  
e) Drug Stability:  
Orally administered drugs can be subject to both acid base hydrolysis and 
enzymatic degradation. Degradation will proceed at the reduced rate for drugs in the 
solid state, for drugs that are unstable in stomach, systems that prolong delivery ever 
the entire course of transit in GI tract are beneficial. Compounds that are unstable in 
the small intestine may demonstrate decreased bioavailability when administered 
form a sustaining dosage from. This is because more drug is delivered in small 
intestine and hence subject to degradation.  
f) Molecular size and diffusivity: 
The ability of drug to diffuse through membrane it‟s so called diffusivity & 
diffusion coefficient is function of molecular size (or molecular weight). Generally, 
values of diffusion coefficient for intermediate molecular weight drugs, through 
flexible polymer range from 10-8 to 10-9 cm
2
 / sec. with values on the order of 10-8 
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being most common for drugs with molecular weight greater than 500, the diffusion 
coefficient  in many polymers frequently are so small that they are difficult to 
quantify i.e. less than 16-12 cm
2
/sec.  Thus high molecular weight drugs and / or 
polymeric drugs should be expected to display very slow release kinetics in sustained 
release device using diffusion through polymer membrane.  
g) Protein binding: 
It is well known that many drugs bind to plasma proteins with a concomitant 
influence on the duration of drug action. Since blood proteins are for the most part re-
circulated and not eliminated, drug Protein binding can serve as a depot for drug 
producing a prolonged release profile, especially if a high degree of drug binding 
occurs.  
Extensive binding to plasma proteins will be evidenced by a long half life of 
elimination for drugs and such drugs generally most require a sustained release 
dosage form. However drugs that exhibit high degree of binding to plasma proteins 
also might bind to bio-polymers in GI tract which could have influence on sustained 
drug delivery.  The presence of hydrophobic moiety on drug molecule also increases 
the binding potential.  
 
1.3.5.2. Biological factors: 
a) Biological Half Life: 
The usual goal of an oral sustained release product is to maintain therapeutic 
blood levels over an extended period. To action this, drug must enter in the circulation 
of approximately the same rate of which it is eliminated. The elimination rate is 
quantitatively described by half-life (t1/2). Therapeutic compounds with short half 
lives are excellent candidates for sustained release preparations. Since this can reduce 
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dosing frequency. In general drugs with half-lives shorter than 3hrs are poor 
candidates of sustained release dosage forms of dose size will increase as well as 
compounds with long half lives, more than 8 hrs are also not used in sustained release 
forms because their effect is already sustained.  
b) Absorption: 
The rate, extent and uniformity of absorption of a drug are important factors 
when considered its formulation into a sustained release system. As the rate limiting 
step in drug delivery from a sustained-release system is its release from a dosage 
form, rather than absorption. Rapid rate of absorption of drug, relative to its release is 
essential if the system is to be successful. It we assume that transit time of drug must 
in the absorptive areas of the GI tract is about 8-12 hrs. The maximum half life for 
absorption should be approximately 3-4 hrs. Otherwise device will pass out of 
potential absorption regions before drug release is complete.  
c) Distribution: 
The distribution of drugs into tissues can be important factor in the overall 
drug elimination kinetics. Since it not only lowers the concentration of circulating 
drug but it also can be rate limiting in its equilibrium with blood and extra vascular 
tissue, consequently apparent volume  of distribution assumes different values 
depending on time course of drug disposition. For design of sustained/ controlled 
release products, one must have information of disposition of drug.  
d) Metabolism: 
Drugs that are significantly metabolized before absorption, either in lumen or 
the tissue of the intestine, can show decreased bioavailability from slower-releasing 
dosage forms. Most intestinal wall enzymes systems are saturable. As drug is released 
at a slower rate to these regions less total drug is presented to the enzymatic. Process 
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device a specific period, allowing more complete conversion of the drug to its 
metabolite. 
e) Side effects: 
 The incidence of side effect of a drug is depends on its therapeutic 
concentration level in blood. It can be remedy by the drug concentration level is 
controlled at which timing that drug exists in blood after administration. Toxic effect 
of a drug is expected above the maximum effective range level and fall in the 
therapeutic effect if a drug below the level of minimum effective range. So the above 
problem we can solve by making sustained release preparation. 
f) Margin of safety:
 
 Therapeutic index of a drug is very important for either sustained or controlled 
release delivery system. Its value only desired the margin of safety. Therapeutic index 
value it has been longer means excellent for preparation of sustained release tablet. 
Narrow therapeutic index of some drug precise to release the active content in 
therapeutic safe and effective range. Some drug like cardiac glycosides that 
therapeutic index value is very small, so it‟s not used for sustained release delivery 
system.   
              Therapeutic index = TD50 ∕ ED50 
Where, TD50 - Median toxic dose 
             ED50 - Median effective dose. 
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1.4. Oral controlled and sustained release systems:      (Chein Y.W., 2009; 
http://www.pharmainfo.net; Shalin A. Modi, et al., 2011) 
The controlled release systems for oral use are mostly solids and based on 
dissolution, diffusion or a combination of both mechanisms in the control of release 
rate of drug. Depending upon the manner of drug release, these systems are classified 
as follows: 
 
1.4.1. Continuous release systems: 
These systems release the drug for a prolonged period of time along the entire 
length of gastrointestinal tract with normal transit of the dosage form. The various 
systems under this category are as follow, 
A. Dissolution controlled release systems 
B. Diffusion controlled release systems 
C. Dissolution and diffusion controlled release systems 
D. Ion exchange resin- drug complexes 
E. pH dependent formulation 
F. Osmotic pressure controlled systems 
A. Dissolution controlled release systems: 
These types of systems are easiest to design. The drug present in such system 
may be the one: 
 With inherently slow dissolution rate e.g. Griseofulvin and Digoxin. 
 That produces slow dissolving forms, when it comes in contact with GI        
             fluids. 
 Having high aqueous solubility and dissolution rate. 
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Drugs having high aqueous solubility and dissolution rate, shows challenge in 
controlling their dissolution rate. Dissolution-controlled release can be obtained by 
slowing the dissolution rate of a drug in the GI medium, incorporating the drug in an 
insoluble polymer and coating drug particles or granules with polymeric materials of 
varying thickness. The rate limiting step for dissolution of a drug is the diffusion 
across the aqueous boundary layer. The solubility of the drug provides the source of 
energy for drug release, which is countered by the stagnant-fluid diffusional boundary 
layer. The rate of dissolution (dm/dt) can be approximated by below equation.  
Dm/dt = ADS/h 
Where, S = Aqueous solubility of the drug. 
            A = Surface area of the dissolving particle or tablet. 
            D = Diffusivity of the drug and 
            h = Thickness of the boundary layer. 
a) Matrix (or monolithic) dissolution controlled systems: 
As the drug is homogeneously dispersed throughout the rate controlling 
medium, this system is also called as monolith system. It is very common and 
employs waxes such as bees wax, carnauba wax which control the drug release rate 
by controlling the rate of dissolution fluid penetration into the matrix by altering the 
porosity of tablet, decreasing its wettability or by itself getting dissolved at a slower 
rate. The drug release is often first order from such matrices. 
b) Reservoir (Encapsulation) dissolution controlled systems: 
In this type, the drug particles are coated or encapsulated by one of the several 
microencapsulation techniques with slowly dissolving materials like cellulose and 
polyethylene glycol. The dissolution rate of coat depends upon the solubility and 
thickness of the coating. 
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B. Diffusion controlled systems: 
The basic mechanism of drug release from these two systems is fundamentally 
different besides these simple systems, combination of reservoir and monolithic 
systems also exist in practice. Diffusion systems are characterized by release rate of 
drug is dependent on its diffusion through inert water insoluble membrane barrier.  
There are basically two types of diffusion devices.  
a) Reservoir devices    
b) Matrix devices  
a) Reservoir Devices: 
Reservoir Devices are those in which a core of drug is surrounded by 
polymeric membrane. The nature of membrane determines the rate of release of drug 
from system. The process of diffusion is generally described by a series of equations 
governed by Fick‟s first law of diffusion.  
J = -D (DC/ DX)……. (1) 
Where, „J‟ is the flux of drug across the membrane given in units of amount / area 
time.  
„D‟ is diffusion coefficient of drug in membrane in units of area / time. This is 
reflecting to drug molecule‟s ability to diffuse through the solvent and is dependent 
on the factors as molecular size and charge.  
„dc/dt‟ represents rate of change in concentration C relative to a distance X in 
the membrane.  
The law states that amount of drug passing across a unit area, is proportional 
to the concentration difference across that plane.  
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Figure 1.3: Schematic representation of reservoir diffusion device Cm (o), and Cm                                                  
                  (d) represent concentration of drug inside surfaces of membrane and C (o)        
                  & C(d) represents concentration in adjacent  regions.  
If it is assumed that the drug on the both side of membrane is in equilibrium 
with its respective membrane surface which in equilibrium between the membrane 
surfaces and their bathing solutions as shown in Figure. Therefore the concentration 
just inside the membrane surface can be related to the concentration in the adjacent 
region by following expression.  
K = Cm (o) / C(d)      at  X = o                                  (2) 
K = Cm (d) / C(d)     at  X = d                                  (3) 
Where K = partition coefficient.  
If we consider K & D are constants then equation (1) becomes,  
J = D K C/d                                                            (4) 
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Where c is the concentration difference across the membrane and d is path length 
of diffusion. The simplest system to consider is that of slab, where drug release is 
from only one surface as shown Figure  in this case equation (4) becomes  
dMt/ dt  =    ADK C/ d                                           (5) 
 
Non permeable polymer shell 
Figure 1.4: Diagrammatic representation of slab configuration of reservoir diffusion       
                    system. 
 
Where Mt = Mass of drug released after time t, dMt/dt. Steady state drug release rate 
of time„t‟; A= surface area of device.  
 
In equation (7) if variables of right side of equation remain constant, then left 
side of equation represents release rate of system, a true controlled release system 
with a zero-order release rate.  
A constant effective area of diffusion, diffusional path length, concentration 
difference, and diffusion coefficient are required to obtain a release rate that is 
constant. Reservoir diffusional systems have several advantages over conventional 
dosage forms. They can after zero order release of drug, kinetics of which can be 
controlled by changing the characteristics of the polymer to meet the particular drug 
and therapy conditions.  
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Figure 1.5: Plot showing approach to steady state for reservoir device that has been 
stored for an extended period (the burst effect curve) and for device that 
has been freshly made (the time lag curve).  
 
Common methods used to develop reservoir type of devices include micro 
encapsulation of drug particles and press coating of tablets containing drug cores. In 
most cases particles coated by microencapsulation form a system where the drug is 
contained in the coating film as well as in the core of micro capsule. The drug release 
generally involves combination of dissolution and diffusion with dissolution being 
process that controls the release rate. If encapsulating material is selected properly 
will be the controlling process. Some materials such as membrane barrier coat alone 
or in combination, are hardened gelatin, methyl or methylcellulose, polyhydroxy 
methacrylate hydroxypropyl methylcellulose, polydroxy methacrylate, polyvinyl 
acetate & various waxes.  
 
Matrix devices:  
 A matrix device, as the name implies, consists of drug dispersed 
homogenously throughout a polymer.  
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Figure 1.6: Matrix diffusion system before release (time=0) & after partial drug     
                    Release (time=t).  
 
In this model drug in outside layer exposed to the bathing solution is dissolved 
first and diffused out of the matrix.  This process continues with the interface 
between  bathing solution and the solid drug moving controlled, the rate of dissolution 
of drug particles within the matrix must be faster that the diffusion rate of dissolved 
drug leaving matrix.  
Following assumptions are made in retrieving the mathematical models are:  
i. A pseudo steady state is maintained during drug release.  
ii. The diameter of drug particles is less than the average distance of drug Diffusion 
through the matrix.  
iii. The bathing solution provides sink conditions.  
iv. The diffusion coefficient of drug in the matrix remains constant.  
 The next equation that describes the rate of release drugs dispersed in an inert 
matrix system has been derived by Higuchi.  
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Figure 1.7: Schematic representation of the physical model used for a planer slab    
                    matrix diffusion device.  
 The change in amount of drug released per unit area dM and change in the 
thickness of the zone of the matrix that has been depleted of the drug,  
dM/dh = Co dh – Cs /2                                               (6) 
By Fick‟s first law,  
dm = (Dm Cs/h) dt.                                                      (7) 
where, Dm is diffusion coefficient in matrix if equation (6)  & (7) are equated & 
solved for D that value of h sustituted back into the integrated form of equation (7) An 
equation for M is obtained.  
M= [Cs Dm (2Co – Cs) t] ½                                         (8) 
Similarly, a drug released from porous or granular matrix is described.  
                         M= [Ds Ca (є/τ) (2Co – є Ca) t] ½                               (9) 
Where,   e = Porosity of matrix  
               τ = tortuosity.  
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              Ca = Solubility of drug in release medium  
              Ds = diffusion coefficient of drug in release medium.  
 In this system drug is leached from matrix through channels or pores.  
  M = Kt½ 
                              M = K √t                         (10) 
Where K is constantan so, that plot amount of drug released verses square root of time 
should be linear if the release of drug from the matrix is diffusion controlled.  The 
release rate of drug from such a device is not zero order, since if decreases with time 
but as previously mentioned, this may be clinically equivalent to constant drugs.  
1.5. Matrix tablets: (Chein Y.W., 2009; Harnish Patel, et al., 2011) 
Introduction of matrix tablet as sustained release (SR) has given a new 
breakthrough for novel drug delivery system (NDDS) in the field of Pharmaceutical 
technology. It excludes complex production procedures such as coating and 
pelletization during manufacturing and drug release rate from the dosage form is 
controlled mainly by the type and proportion of polymer used in the preparations. 
Hydrophilic polymer matrix is widely used for formulating SR dosage form. 
 Because of increased complication and expense involved in marketing of new 
drug entities, has focused greater attention on development of sustained release or 
controlled release drug delivery systems.  
Matrix systems are widely used for the purpose of sustained release. It is the 
release system which prolongs and controls the release of the drug that is dissolved or 
dispersed. In fact, a matrix is defined as a well-mixed composite of one or more drugs 
with gelling agent i.e. hydrophilic polymers. By the sustained release method 
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therapeutically effective concentration can be achieved in the systemic circulation 
over an extended period of time, thus achieving better compliance of patients. 
 Numerous SR oral dosage forms such as membrane controlled system, 
matrices with water soluble/insoluble polymers or waxes and osmotic systems have 
been developed, intense research has recently focused on the designation of SR 
systems for poorly water soluble drugs. 
 
1.5.1. Advantages of matrix tablets: 
 Easy to manufacture  
 Versatile, effective and low cost  
 Can be made to release high molecular weight compounds  
 The sustained release formulations may maintain therapeutic 
concentrations over prolonged periods.  
 The use of sustain release formulations avoids the high blood 
concentration.  
 Sustain release formulations have the potential to improve the patient 
compliance.  
 Reduce the toxicity by slowing drug absorption.  
 Increase the stability by protecting the drug from hydrolysis or other 
derivative changes in gastrointestinal tract.  
 Minimize the local and systemic side effects.  
 Improvement in treatment efficacy.  
 Minimize drug accumulation with chronic dosing.  
 Usage of less total drug.  
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 Improvement the bioavailability of some drugs.  
 Improvement of the ability to provide special effects.  
Ex: Morning relief of arthritis through bed time dosing. 
 
1.5.2. Disadvantages of matrix tablet: 
 The remaining matrix must be removed after the drug has been 
released.  
 High cost of preparation.  
 The release rates are affected by various factors such as, food and the 
rate transit through the gut.  
 The drug release rates vary with the square root of time. Release rate 
continuously diminishes due to an increase in diffusional resistance 
and/or a decrease in effective area at the diffusion front. However, a 
substantial sustained effect can be produced through the use of very 
slow release rates, which in many applications are indistinguishable 
from zero-order.  
 
1.5.3. Classification of matrix tablets:  
1.5.3.1. On the Basis of Retardant Material Used:  
Matrix tablets can be divided into 5 types.   
1. Hydrophobic Matrices (Plastic matrices): 
The concept of using hydrophobic or inert materials as matrix materials was 
first introduced in 1959. In this method of obtaining sustained release from an oral 
dosage form, drug is mixed with an inert or hydrophobic polymer and then 
compressed in to a tablet.  
Sustained release is produced due to the fact that the dissolving drug has 
diffused through a network of channels that exist between compacted polymer 
particles. Examples of materials that have been used as inert or hydrophobic matrices 
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include polyethylene, polyvinyl chloride, ethyl cellulose and acrylate polymers and 
their copolymers. The rate-controlling step in these formulations is liquid penetration 
into the matrix. The possible mechanism of release of drug in such type of tablets is 
diffusion. Such types of matrix tablets become inert in the presence of water and 
gastrointestinal fluid.  
2. Lipid Matrices:  
 These matrices prepared by the lipid waxes and related materials. Drug 
release from such matrices occurs through both pore diffusion and erosion. Release 
characteristics are therefore more sensitive to digestive fluid composition than to 
totally insoluble polymer matrix. Carnauba wax in combination with cetyl alcohol or 
stearic acid has been utilized for retardant base for many sustained release 
formulation.  
3. Hydrophilic Matrices:  
Hydrophilic polymer matrix systems are widely used in oral controlled drug 
delivery because of their flexibility to obtain a desirable drug release profile, cost 
effectiveness, and broad regulatory acceptance. The formulation of the drugs in 
gelatinous capsules or more frequently, in tablets, using hydrophilic polymers with 
high gelling capacities as base excipients is of particular interest in the field of 
controlled release. Infect a matrix is defined as well mixed composite of one or more 
drugs with a gelling agent (hydrophilic polymer). These systems are called swellable 
controlled release systems.  
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The polymers used in the preparation of hydrophilic matrices are divided into 
three broad groups,  
A. Cellulose derivatives:  
 Methylcellulose 400  and  4000Cps,  Hydroxy ethylcellulose; Hydroxypropyl 
methylcellulose (HPMC) 25, 100, 4000 and 15000Cps; and Sodium carboxy methyl 
cellulose.  
B. Non cellulose natural or semi synthetic polymers:  
Agar-Agar; Carob gum; Alginates; Molasses; Polysaccharides of mannose and 
galactose, Chitosan and Modified starches.  
Polymers of acrylic acid:  
Carbopol-934, the most used variety. 
4. Biodegradable Matrices:  
These consist of the polymers which comprised of monomers linked to one 
another through functional groups and have unstable linkage in the backbone. They 
are biologically degraded or eroded by enzymes generated by surrounding living cells 
or by non-enzymatic process in to oligomers and monomers that can be metabolized 
or excreted. Examples are natural polymers such as proteins and polysaccharides; 
modified natural polymers; synthetic polymers such as aliphatic poly (esters) and poly 
anhydrides. 
5. Mineral Matrices:  
These consist of polymers which are obtained from various species of 
seaweeds. Example is Alginic acid which is a hydrophilic carbohydrate obtained from 
species of brown seaweeds (Phaephyceae) by the use of dilute alkali.  
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1.5.3.2. On the Basis of Porosity of Matrix:  
Matrix system can also be classified according to their porosity and 
consequently, Macro porous; Micro porous and Non-porous systems can be 
identified:  
1. Macro porous Systems:  
In such systems the diffusion of drug occurs through pores of matrix, which 
are of size range 0.1 to 1 μm. This pore size is larger than diffusant molecule size.  
2. Micro porous System:  
Diffusion in this type of system occurs essentially through pores. For micro 
porous systems, pore size ranges between 50 – 200 A°, which is slightly larger than 
diffusant molecules size. 
 3. Non-porous System:  
Non-porous systems have no pores and the molecules diffuse through the 
network meshes. In this case, only the polymeric phase exists and no pore phase is 
present.  
 
1.5.4. Polymers used in matrix tablet:  
Hydrogels:  
Polyhydroxy ethyl methacrylate (PHEMA), Cross-linked polyvinyl alcohol 
(PVA), Cross-linked polyvinyl pyrrolidone (PVP), Polyethylene oxide (PEO), Poly 
acrylamide (PA). 
Soluble polymers:  
Polyethyleneglycol (PEG), polyvinyl alcohol (PVA), Polyvinyl pyrrolidone 
(PVP), Hydroxypropyl methyl cellulose (HPMC).  
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Biodegradable polymers:  
Polylactic acid (PLA), Polyglycolic acid (PGA), Poly caprolactone (PCL), 
Poly anhydrides, Poly orthoesters.  
Non-biodegradable polymers:  
Polyethylene vinyl acetate (PVA), Poly dimethyl siloxane (PDS), Polyether 
urethane (PEU), Polyvinyl chloride (PVC), Cellulose acetate (CA), Ethyl cellulose 
(EC).  
Mucoadhesive polymers:  
Poly carbophil, Sodium carboxy methylcellulose, Polyacrylic acid, 
Tragacanth, Methyl cellulose, Pectin.  
Natural gums: Xanthan gum, Guar gum, Karaya gum, Locust bean gum. 
 
1.5.5. Mechanism of drug release from matrix tablet: 
Drug in the outside layer exposed to the bathing solution is dissolved first and 
then diffuses out of the matrix. This process continues with the interface between the 
bathing solution and the solid drug moving toward the interior. It follows that for this 
system to be diffusion controlled, the rate of dissolution of drug particles within the 
matrix must be much faster than the diffusion rate of dissolved drug leaving the 
matrix. Derivation of the mathematical model to describe this system involves the 
following assumptions:  
a) A pseudo-steady state is maintained during drug release,  
b) The diameter of the drug particles is less than the average distance of drug 
diffusion through the matrix,  
c) The bathing solution provides sink conditions at all times.  
 
Venlafaxine Sustained Release Matrix Tablets                  INTRODUCTION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  29 
 
1.6. Methods used in tablet manufacturing:   (Lieberman H.A. and Lachman L., 
1999; Ansel H.C., 2009; http://www.pharmainfo.net) 
Granulation:       
 Granulation may be defined as a size enlargement process which converts 
small particles into physically stronger & larger agglomerates. 
The reason for granulation: 
  Become the pharmaceutical ingredient are free flowing 
  Increase the denseness of  ingredient 
  We can formulate uniform granular size that does not existing apart  
  Produce better  compression  characteristic  of  drug 
  Controlling  the  rate of  drug release from the dosage form 
  Reduce  dust in granulation technique 
  The  appearance  of  tablet can be achieved 
Methods: 
  1. Direct compression  
  2. Wet granulation 
  3. Dry granulation     
1.6.1. Direct compression: 
                In early days, most of the tablets require granulation of the powdered Active 
Pharmaceutical Ingredient (API) and Excipients. At the availability of new excipients 
or modified form of old excipients and the invention of new tablet machinery or 
modification of old tablet machinery provides an ease in manufacturing of tablets by 
simple procedure of direct compression. 
            Amongst the techniques used to prepare tablets, direct compression is the most 
advanced technology. It involves only blending and compression. Thus offering 
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advantage particularly in terms of speedy production. Because it requires fewer unit 
operations, less machinery, reduced number of personnel and considerably less 
processing time along with increased product stability. 
1.6.1.1. Definition:  
 The term “direct compression” is defined as the process by which tablets are 
compressed directly from powder mixture of API and suitable excipients. No 
pretreatment of the powder blend by wet or dry granulation procedure is required. 
1.6.1.2. The events that motivates the industry people to use direct compression 
technique:  
I. Commercial availability of the directly compressible excipients possessing         
both good compressibility and good flowability. For example,  
Spray dried lactose, Anhydrous lactose, Starch-1500, microcrystalline cellulose, Di-
Pac
Ò
, sorbitol. 
II. Major advances in tablet compression machinery: 
i)  Improved positive die feeding, 
ii) Precompression of powder blend. 
1.6.1.3 Merits: 
i) Direct compression is more efficient and economical process as compared to other 
processes, because it involves only dry blending and compaction of API and 
necessary excipients. 
ii) The most important advantage of direct compression is economical process. 
Reduced processing time, reduced labor costs, fewer manufacturing steps, and less 
number of equipments are required, less process validation, reduced consumption of 
power.  
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iii) Elimination of heat and moisture, thus increasing not only the stability but also the 
suitability of the process for thermolabile and moisture sensitive API‟s. 
iv) Particle size uniformity. 
v) Prime particle dissolution. 
 In case of directly compressed tablets after disintegration, each primary drug 
particle is liberated. While in the case of tablets prepared by compression of granules, 
small drug particles with a larger surface area adhere together into larger 
agglomerates; thus decreasing the surface area available for dissolution. 
vi) The chances of batch-to-batch variation are negligible, because the unit operations 
required for manufacturing processes is fewer. 
vii) Chemical stability problems for API and excipient would be avoided. 
viii) Provides stability against the effect of aging which affects the dissolution rates. 
1.6.1.4. Merits over wet granulation process: 
 The variables faced in the processing of the granules can lead to significant 
tableting problems. Properties of granules formed can be affected by viscosity of 
granulating solution, the rate of addition of granulating solution, type of mixer used 
and duration of mixing, method and rate of dry and wet blending. The above variables 
can change the density and the particle size of the resulting granules and may have a 
major influence on fill weight and compaction qualities. Drying can lead to 
unblending as soluble API migrates to the surface of the drying granules. 
1.6.1.5. Demerits: 
Excipients Related:  
i) Problems in the uniform distribution of low dose drugs. 
ii) High dose drugs having high bulk volume, poor compressibility and poor 
flowability are not suitable for direct compression. 
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iii) The choice of excipients for direct compression is extremely critical. 
Direct compression diluents and binders must possess both good 
compressibility and good flow ability. 
iv)  Many active ingredients are not compressible either in crystalline or 
amorphous forms. 
v) Direct compression blends may lead to unblending because of difference 
in particle size or density of drug and excipients. Similarly the lack of 
moisture may give rise to static charges, which may lead to unblending. 
vi) Non-uniform distribution of colour, especially in tablets of deep colours. 
Process Related: 
i) Capping, lamination, splitting, or layering of tablets is sometimes related to air 
entrapment during direct compression. When air is trapped, the resulting tablets 
expand when the pressure of tablet is released, resulting in splits or layers in the 
tablet. 
ii) In some cases require greater sophistication in blending and compression 
equipments. 
iii) Direct compression equipments are expensive. 
1.6.1.6. Manufacturing steps for direct compression: 
 Direct compression involves comparatively few steps: 
  Milling of drug and excipients. 
  Mixing of drug and excipients. 
  Tablet compression. 
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Figure 1.8: Manufacturing Steps for Direct Compression. 
1.6.1.7. Direct compression Excipients: 
 Direct compression excipients mainly include diluents, binders and 
disintegrants. Generally these are common materials that have been modified during 
the chemical manufacturing process, in such a way to improve compressibility and 
flowability of the material. 
 The physicochemical properties of the ingredients such as particle size, 
flowability and moisture are critical in direct compression tableting. The success of 
direct compression formulation is highly dependent on functional behavior of 
excipients. 
1.6.1.7.1. An ideal direct compression excipient should possess the following 
attributes:  
 i)  It should have good compressibility. 
ii) It should possess good hardness after compression, that is material should not 
possess any deformational properties; otherwise this may lead to capping and 
lamination of tablets. 
iii) It should have good flowability. 
iv) It should be physiologically inert. 
v) It should be compatible with wide range of API. 
vi) It should be stable to various environmental conditions (air, moisture, heat, etc.). 
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vii) It should not show any physical or chemical change in its properties on aging. 
viii) It should have high dilution potential i.e. able to incorporate high amount of API. 
 ix) It should be colourless, odorless and tasteless. 
x) It should accept colourants uniformity. 
xi) It should possess suitable organoleptic properties according to formulation type, 
that is in case of chewable tablet diluent should have suitable taste and flavor. For 
example, mannitol produces cooling sensation in mouth and also sweet test. 
xii) It should not interfere with bioavailability and biological activity of active 
ingredients. 
xiii) It should be easily available and economical in cost. 
Granulation method can be broadly classified into two types:  
 Wet granulation and  
 Dry granulation. 
 
1.6.2. Wet granulation: 
The most widely used process of agglomeration in pharmaceutical industry is 
wet granulation. Wet granulation process simply involves wet massing of the powder 
blend with a granulating liquid, wet sizing and drying. 
1.6.2.1. Important steps involved in the wet granulation: 
i)   Mixing of the drug(s) and excipients 
ii)  Preparation of binder solution 
iii) Mixing of binder solution with powder mixture to form wet mass. 
iv) Coarse screening of wet mass using a suitable sieve (6-12 # screens). 
v)  Drying of moist granules. 
vi) Screening of dry granules through a suitable sieve (14-20 # screen). 
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vii)  Mixing of screened granules with disintegrant, glidant, and lubricant. 
1.6.2.2. Limitations of wet granulation: 
i)  The greatest disadvantage of wet granulation is its cost. It is an expensive process 
because of labor, time, equipment, energy and space requirements. 
ii) Loss of material during various stages of processing  
iii) Stability may be major concern for moisture sensitive or thermo labile drugs  
iv) Multiple processing steps add complexity and make validation and control 
difficult. 
v) An inherent limitation of wet granulation is that any incompatibility between 
formulation components is aggravated. 
 
1.6.3. Dry granulation: 
In dry granulation process the powder mixture is compressed without the use 
of heat and solvent. It is the least desirable of all methods of granulation. The two 
basic procedures are to form a compact of material by compression and then to mill 
the compact to obtain a granules. Two methods are used for dry granulation. The 
more widely used method is slugging, where the powder is pre-compressed and the 
resulting tablet or slug are milled to yield the granules.  
The other method is to pre-compress the powder with pressure rolls using a 
machine such as Chilosonator. 
1.6.3.1. Advantages: 
The main advantages of dry granulation or slugging are that it uses less 
equipments and space. It eliminates the need for binder solution, heavy mixing 
equipment and the costly and time consuming drying step required for wet 
granulation. Slugging can be used for advantages in the following situations: 
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i) For moisture sensitive material 
ii) For heat sensitive material 
iii) For improved disintegration since powder particles are not bonded together by a 
binder 
1.6.3.2. Disadvantages: 
i) It requires a specialized heavy duty tablet press to form slug 
ii) It does not permit uniform colour distribution   
iii) Achieved with wet granulation where the dye can be incorporated into binder 
liquid. 
iv) The process tends to create more dust than wet granulation, increasing the 
potential contamination. 
 
1.7. DEPRESSION:     (http://www.about.com) 
Depression makes a person feel sad, hopeless, worthless, pessimistic and 
guilty. Often the sufferer has difficulty concentrating and making decisions, has a loss 
of appetite and weight or a weight gain, has difficulty sleeping, has a lack of energy 
and sometimes physical symptoms such as slow movement and speech. Depression 
must be taken seriously because of the high rate of suicide associated with it. 
 1.7.1. Most common types of depression  
The following are descriptions of the most common types of depression. 
1. Major Depressive Disorder 
When people use the terms depression or clinical depression, they are 
generally referring to major depressive disorder. Major depressive disorder is a mood 
disorder characterized by a depressed mood, a lack of interest in activities normally 
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enjoyed, changes in weight and sleep, fatigue, feelings of worthlessness and guilt, 
difficulty concentrating and thoughts of death and suicide. If a person experiences the 
majority of these symptoms for longer than a two-week period, they may be 
diagnosed with major depressive disorder.  
2. Dysthymic Disorder 
Dysthymia (pronounced Dis-THIGH-me-uh) comes from the Greek roots dys, 
meaning "ill" or "bad," and thymia, meaning "mind" or "emotions." The terms 
dysthymia and dysthymic disorder refer to a mild to moderate, chronic state of 
depression.  
3. Bipolar Disorder 
Bipolar disorder is an illness that consists of alternating periods of elevated 
moods, called manic episodes, and depression. Mood swing run on a spectrum from 
mild mania (called hypomania) to more severe, debilitating highs. Periods of mania 
can last for hours, days, weeks or even months before depression returns.  
4. Postpartum Depression 
Pregnancy brings about many hormonal shifts. These dramatic shifts can 
sometimes affect mood. This is commonly known as the "baby blues." Postpartum 
depression can be more than just a case of the blues, however. It can range from mild 
symptoms that go away without treatment all the way up to postpartum psychosis, 
which left untreated, may be responsible for tragic murders of children.  
5. Seasonal Affective Disorder 
If you experience depression, sleepiness, weight gain and carbohydrate 
cravings during the winter months, but feel great as soon as spring returns, you may 
have a condition called Seasonal Affective Disorder (SAD).  
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6. Premenstrual Dysphoric Disorder 
The most frequently reported symptoms of premenstrual syndrome (PMS) 
include irritability, fatigue, anxiety, nervous tension, mood swings, depression, 
feeling overwhelmed or out of control, physical symptoms of swelling or bloating of 
the abdomen or extremities, appetite changes and food cravings, aches, and breast 
tenderness. These symptoms may occur for several days to 2 weeks before menses but 
subside with the onset of the menstrual period. When these symptoms, especially 
those of mood, are severe, a diagnosis of premenstrual dysphoric disorder (PMDD) 
may be made.  
7. Atypical Depression 
Do you experience symptoms such as improved mood when good things 
happen, overeating, sleeping too much or sensitivity to rejection? These are symptoms 
characteristic of atypical depression, which is a type of depression which does not 
follow the "typical" set of depression symptoms, such as a lack of appetite and 
insomnia. It is actually more common than the name might imply.  
 
1.7.2. Etiology of depressions   
 Though there are several theories about what cause classical depressions, 5-
HT plays an important role in the genesis of depressive psychosis as evidenced by 
increasing in 5-HT (or) its precursors in the brain in patients of depressive psychosis. 
Many drugs (antidepressants) based on 5-HT metabolization and activations are now 
available. They prevent the uptake of 5-HT from serotonergic nerve endings, thereby 
increasing endogeneous 5-HT levels. 
 Similarly, noradrenaline (NAD) also plays an important role in the genesis of 
depression as its absence in various areas of the CNS leads to the development of 
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depressions. Antidepressant like MAO and SNRI act by inhibiting the metabolism of 
NAD (or) preventing its reuptake into the adrenergic nerve ending. 
1.7.3. Symptoms and Signs of Depression  
Depression is not something you feel for a day or two before feeling better. In 
true depressive illnesses, the symptoms last weeks, months, or sometimes years if you 
don't seek treatment. If you are depressed, you are often unable to perform daily 
activities. You may not care enough to get out of bed or get dressed, much less work, 
do errands, or socialize. 
 Adults: You may be said to be suffering from a major depressive episode if you 
have a depressed mood for at least two weeks and have at least five of the 
following clinical symptoms: 
o Feeling sad or blue 
o Crying spells 
o Loss of interest or pleasure in usual activities 
o Significant increase or decrease in appetite 
o Significant weight loss or weight gain 
o Change in sleep pattern: inability to sleep or excessive sleeping 
o Agitation or irritability 
o Fatigue or loss of energy 
o A tendency to isolate from friends and family 
o Trouble concentrating 
o Feelings of worthlessness or excessive guilt 
o Thoughts of death or suicide 
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1.7.4. Facts/Statistics of Depression 
 Depression affects about 19 million Americans annually. It is estimated to 
contribute to half of all suicides. About 5%-10% of women and 2%-5% of men will 
experience at least one major depressive episode during their adult life. Depression 
affects people of genders, as well as all races, incomes, ages, and ethnic and religious 
backgrounds. However, it is twice as common in women compared to men and three 
to five times more common in the elderly than in young people 
 
1.7.5. Diagnosis of Depression  
Many providers of health care may help diagnose clinical depression: licensed 
mental-health therapists, family physicians, or other primary-care providers, 
specialists whom you see for a medical condition, emergency physicians, 
psychiatrists, psychologists, psychiatric nurses, and social workers. 
If one of these professionals suspects that you have depression, you will 
undergo an extensive medical interview and physical examination. As part of this 
examination, you may be asked a series of questions from a standardized 
questionnaire or self-test to help assess your risk of depression and suicide. 
Depression may be associated with a number of other medical conditions or 
can be a side effect of various medications. For this reason, routine laboratory tests 
are often performed during the initial evaluation to rule out other causes of your 
symptoms. Occasionally, an X-ray, scan, or other imaging study may be needed 
 
1.7.6. Treatment of Depression 
If your symptoms indicate that you have clinical depression, your health-care 
provider will strongly recommend treatment. Treatment may include addressing any 
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medical conditions that cause or worsen depression. For example, an individual who 
is found to have low levels of thyroid hormone might receive thyroid hormone 
replacement with levothyroxine (Synthroid, Levoxyl). Other components of treatment 
may be supportive therapy, such as changes in lifestyle and behavior, psychotherapy, 
complementary therapies, and may often include medication. If your symptoms of 
depression are severe enough to warrant treatment with medication, you are most 
likely to feel better faster and for longer when medication treatment is combined with 
psychotherapy. 
Most practitioners will continue treatment of major depression for six months 
to a year. Treatment for teens with depression can have a significantly positive effect 
on the adolescent's functioning with peers, family, and at school. Without treatment, 
your symptoms will last much longer and may never get better. In fact, they may get 
worse. With treatment, your chances of recovery are quite good.  
 
1.7.7. Prevention of Depression 
People who have risk factors for depression should be "screened" regularly by 
their health-care provider. This means that when they see their health-care provider, 
questions should be asked that might indicate depression. 
If identified early, those who are at risk for depression are more likely to 
benefit from treatment.                 
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2. NEED AND OBJECTIVES 
 
  
Need of this work are: 
 Venlafaxine Hydrochloride is the most widely used anti- depressant agent in 
the treatment of major depression disease has a low bioavailability, because of 
its poor absorption. It undergoes hepatic metabolism and its mean elimination 
half life (5 hours) drug requires frequent dosing by oral route, of various 
recent techniques for controlling drug release, matrix system offer various 
advantages of ease of formulation better control on release profile of drug and 
better patient compliance. 
 The pronounced fluctuation resulting from the conventional drug 
administration are likely to yield period of therapeutic effects when the 
concentration falls below the minimum therapeutic drug concentration and can 
be controlled within the narrow therapeutic range by use of sustained release 
system. Which will minimize the severity of side effects.  
  Hydrophobic polymer matrix system are widely used for designing oral 
sustained release drug delivery dosage form because of their flexibility to 
provide a desirable drug release profile, cost effectiveness and broad 
regulatory acceptance.  
 Large scale production needs more simplicity in the formulation with 
economic and cheapest dosage form. The matrix tablets formulation by wet 
granulation method is most acceptable in large scale production.
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Objectives of the work are: 
 To  evaluate the physical characters of prepared sustained release tablets  
 To  elucidate the effect of polymer composition, on the release kinetics and  
 To determine the chemical compatibility of formulation containing various 
ratios of polymer and drug.  
Conventional oral formulations of Venlafaxine Hydrochloride  are administered 
multiple times a day (75 to 225 mg) because of its moderate half-life (t1/2 = 5 hours). 
Treatment of Depression using conventional formulations of Venlafaxine 
Hydrochloride is found to have many drawbacks, such as adverse side effects 
resulting from accumulation of drug in multi-dose therapy, poor patient compliance, 
and high cost. Sustained release once-daily formulations of Venlafaxine 
Hydrochloride can overcome some of these problems. 
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3. PLAN OF WORK 
 
The present work was carried out to design and evaluate sustained-release 
tablets of Venlafaxine Hydrochloride, an antidepressant drug. The sustained-release  
matrix tablets were prepared by Hot melt granulation using carnauba wax, cetyl 
alcohol, stearic acid, lactose,  and talc keeping in view the objectives described above 
the following plan of work was adopted. 
THE SCHEME OF THE ENTIRE WORK IS LISTED AS FOLLOWS: 
 Literature review 
 Selection of drug and excipients 
 Procurement of drug and excipients 
 Physicochemical studies (organoleptic properties, melting point and solubility)  
  Standardization of the method and construction of calibration curve for the 
estimation of Venlafaxine Hydrochloride, quantification of drug. 
  Compatibility studies of drug and polymer by FTIR spectral and DSC studies 
 Formulation of Venlafaxine Hydrochloride sustained release matrix tablets by 
using polymers like carnauba wax,  cetyl alcohol and stearic acid by Hot melt 
granulation method. 
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   Evaluation of  prepared granules (pre-compression parameters) 
i. Angle of repose 
ii. Determination of bulk density 
iii. Determination of tapped density 
iv. Compressibility index 
v. Hausner ratio 
   Evaluation of physical parameters of Venlafaxine sustained-release tablets 
(post-compression parameters) 
                      i.    Thickness and diameter 
 ii.    Hardness 
iii. Friability 
iv. Weight variation 
v. Drug content  
 Evaluation of in vitro release characteristics of all formulations by using USP 
dissolution apparatus type I (Basket). 
 To study the mechanism of drug release by applying kinetic parameters. 
 To perform stability studies as per ICH guidelines.
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4. LITERATURE REVIEW 
 
Amelia Avachat., et al. (2007) was developed and characterized an oral 
controlled release drug delivery system for concomitant administration of diclofenac 
sodium (DS) and chondroitin sulfate (CS). A hydrophilic matrix-based tablet using 
different concentrations of hydroxypropyl methylcellulose (HPMC) was developed 
using wet granulation technique to contain 100 mg of DS and 400 mg of CS. 
Formulations prepared were evaluated for the release of DS and CS over a period of 9 
hours in pH 6.8 phosphate buffer using United States Pharmacopoeia (USP) type II 
dissolution apparatus. Along with usual physical properties, the dynamics of water 
uptake and erosion degree of tablets were also investigated. The in vitro drug release 
study revealed that HPMC K100 CR at a concentration of 40% of the dosage form 
weight was able to control the simultaneous release of both DS and CS for 9 hours. 
The release of DS matched with the marketed CR tablet of DS with similarity factor 
(f2) above 50. 
 
Deepak S., et al. (2010) had developed sustained release formulation of 
quetiapine fumarate using HPMC and PVP K30. The study involves fixing the drug 
and polymer ratio for control the drug release up to the desired time. The effect of 
polymer concentration and polymer blend concentration were also studied. 
Dissolution studies were performed in 0.1N HCl for 2 hrs and in phosphate buffer up 
to 12 hours. From the release it was observed that the polymer blend of HPMC/PVP 
K30 were successfully sustained the release of drug up to 12 hrs.  
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Gohel M.C.,  et  al.  (2007)  was developed modified release of isoniazid 
using hydroxypropyl methylcellulose as a rate controlling agent. The low viscosity 
grade hydroxypropyl methylcellulose, medium viscosity grade hydroxypropyl 
methylcellulose and high viscosity grade Hydroxypropyl methylcellulose were used 
to prepare the matrix tablets. The tablets, prepared by direct compression, were 
subjected to physical characterization and in-vitro drug release studies. The release 
rate was strongly influenced by the type of polymer and concentration of polymer. 
 
Harris Shoaib M.,  et  al. (2006)  had formulated a once daily sustained 
release matrix tablet of ibuprofen using HPMC as release controlling factor and to 
evaluate drug release parameters as per various release kinetic models. The tablets 
were directly compressed using Avicel pH 101 and magnesium stearate. Different 
dissolution models were applied to drug release data in order to evaluate release 
mechanism. The drug release data fit well to the Higuchi expression. 
 
Indranil Kumar Yadav., et al. (2010) was developed the oral sustained 
release matrix tablets of aceclofenac using hydrophilic and hydrophobic polymers. 
Aceclofenac is a non steroidal anti-inflammatory agent used in symptomatic treatment 
of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis and its biological 
half life is 4hrs. Controlled release formulations of aceclofenac (200 mg) were 
prepared by direct compression method. The tablets were subjected to 
physicochemical, in-vitro drug release and stability studies. The drug release from 
optimized formulations F1, F4 and F7 was extended for a period of 12 hrs. The 
optimized formulations were subjected to stability studies for three months at 45°C 
temperature with RH 75±5%, and showed stability with respect to physicochemical 
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parameters and release pattern. Results of the present study indicated the suitability of 
hydrophilic and hydrophobic polymers in the preparation of matrix based sustained 
release formulation of aceclofenac. 
 
Kalyani C., et al. (2009) had designed oral sustained matrix tablets of 
zidovudine using HPMC K4M, guar gum and ethyl cellulose as the retardant 
polymers. Factors like polymer proportion, polymer type and effect of filler type on 
the in vitro release of the drug. The formulations were prepared by wet granulation 
technique. The granules were evaluated and all formulations showed compliance with 
pharmacopoeial standards. Formulation F2 and F8 sustained the release for 12 hrs. 
Formulation F5 was found to be best which contains 15% HPMC using MCC as 
diluent release 10 hours only. 
 
               Madhusmruti K., et al. (2010) was developed sustain release matrix 
formulation of Propanolol hydrochloride and investigate the effects of both 
hydrophilic and hydrophobic polymer on in-vitro drug release. Matrix tablets were 
prepared by direct compression method using different concentrations of 
Hydroxypropyl methyl cellulose (HPMC) and Ethyl Cellulose (EC). Prepared 
formulations were subjected to various studies like hardness, friability, thickness, % 
drug content, weight variation, dynamic of water uptake and erosion etc. Tablets were 
subjected to in-vitro drug release in 0.1N HCl (pH 1.2) for first 2 hours followed by 
phosphate buffer (pH 6.8) remaining time. 
 
Patil U.K.,  et  al.  (2008)  prepared and evaluated sustained release matrix 
tablet using natural polymers like pectin, guar gum and xanthan gum. Furosemide is 
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used as the model drug and the formulations were compressed by a direct 
compression. The tablets were evaluated for physical characteristic and all the 
formulations were found to be in acceptable limits. Among the polymers guar gum 
was found to exhibit greater swelling index than pectin and xanthan gum.  
 
            Prabu Moses.,  et  al.  (2010)  had formulated Ciprofloxacin controlled 
release matrix tablets using HPMC K100M, Guar gum, Carboxy methylcellulose, 
starch, polyvinyl pyrrolidone k30, magnesium stearate, isopropyl alcohol. Formulated 
tablets were taken to evaluation studies such as hardness, weight variation, friability, 
drug content and thickness.  
 
Potu Apparao., et al. (2011) had formulated and evaluated gum based 
sustained release matrix tablets of Lamivudine using different natural polymers such 
as Guar gum, Xanthan gum, Rosin gum, Pectin, and Sodium alginate taken at 30%, 
40% and 50% of the total weight of the tablet. Lamivudine is a potent hydrophilic anti 
viral agent indicated for treatment of AIDS (Acquired Immunodeficiency Syndrome). 
All the formulations were able to retard the release of the drug beyond 18 hours 
except pectin and sodium alginate were unable to sustain the drug release from the 
matrix tablets. F5 (40% Xanthan Gum) formulation was selected as optimized 
formulation. 
 
Raghuram Reddy K., et al. (2003) had formulated once daily sustained 
release matrix tablets of nicorandil, a novel potassium channel openers used in the 
treatment of cardiovascular disease. The tablets are prepared by wet granulation 
technique using ethanolic solutions of ethylcellulose (EC), Eudragit RL-100, Eudragit 
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RS-100, and polyvinyl pyrrolidone as granulating agents with hydrophilic matrix 
materials such as HPMC, sodium carboxylic cellulose and sodium alginate.  The 
granules were studied for physiochemical characteristics and for evaluation 
parameters. Granules showed good flow property and tablet formulations are all 
within official limits. From the dissolution studies the formulation F1 could extend 
the release for 24 hrs and thus it exhibited the most successful formulation of the 
study. 
 
Raju Manda., et al. (2010) was developed a sustained release matrix tablet of 
aceclofenac using different natural polymers (Guar gum, Xanthan gum, Chitosan) in 
various proportions as release controlling factor by direct compression method. The in 
vitro dissolution study was carried out for 11 hours using United States 
Pharmacopoeia (USP) 1 Basket-type dissolution apparatus in 0.1N hydrochloric acid 
for first 2 hours and phosphate buffer pH 7.4 for 9 hours. The in vitro release study 
shows that only F9 formulation was releases the drug in a sustained manner for 11 
hours. This study explored the optimum concentration and effect of polymer(s) on 
acelofenac release pattern from the tablet matrix for 11 hour period. 
 
Saleh M. Saidan, et al. (2005) developed guar gum matrix tablets for oral 
controlled release of water-soluble Diltiazem hydrochloride prepared by using 
microcrystalline cellulose, starch, magnesium stearate and talc. In vitro drug release 
studies were performed using USP dissolution rate apparatus. 
 
Sandip B. Tiwari.,  et al.  (2003) had formulated Tramadol hydrochloride 
using hydrophilic and hydrophobic matrix system for controlled release. The effect of 
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concentration of hydrophilic and hydrophobic polymers on the release rate of 
Tramadol was studied. Hydrophilic matrix tablets prepared by wet granulation 
technique, while hydrophobic matrix tablets prepared by melt granulation technique. 
In vitro dissolution studies were performed. 
 
Saravanabhavan Shanmugam., et al. (2010) was developed sustained 
release matrix tablets of aceclofenac. The tablets were prepared with different ratios 
of hydroxypropyl methylcellulose K100M and ethylcellulose by wet granulation 
technique. The solubility study of the aceclofenac was conducted to select a suitable 
dissolution medium for in vitro drug release studies. In vitro dissolution study was 
carried out for all the formulation and the results compared with marketed sustained 
release tablets. The drug release from matrix tablets was found to decrease with 
increase in polymer ratio of hydroxypropyl methylcellulose as well as ethylcellulose. 
Formulation F3 exhibited almost similar drug release profile in different dissolution 
media as that of marketed tablets.  
 
Seema Pushkar.,  et al.  (2009) was developed the extended release tableted 
matrix devices for once daily dosing of diclofenac sodium, and their evaluation for 
performance and compliance with official pharmacopoeial and allied pharmaceutical 
requirements. The matrix tablets were prepared by drug incorporated polymer matrix, 
formulated using different combinations and ratios of hydroxypropyl methylcellulose 
(HPMC), sodium carboxy methylcellulose (Sodium CMC), and sodium alginate 
(NaAlg). Several preformulation trials were conducted to study the effect and 
optimization of various formulation and process parameters. The drug loaded 
polymeric matrices so prepared were compressed to tablets and studied for drug the 
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release behaviour and comparative kinetic characterization along with six popular 
marketed brands of Diclofenac SR tablets. The formulated granules and tablets 
compressed complied with compendial and mechanistic requirements. The in vitro 
results shown a better release profile of formulated delivery system when compared to 
marketed brands extended up to 24 hours. The various formulations have shown an 
extended release up to 11 – 23 hours in different release environments. 
 
Sundaramoorthy K.,  et  al.  (2011) had formulated monolithic matrix tablets 
of metformin hydrochloride as extended release tablets by employing ethyl cellulose 
polymer and the extended release characterization of the formulated tablets was 
investigated. Extended release matrix tablets containing 500 mg metformin 
hydrochloride were developed by changing concentration of drug: polymer (EC) in 
the ratio of 5:1, 5:2, 5:3 and 5:4 by direct compression. Formulations were optimized 
based on the acceptable tablet properties in-vitro and in-vivo drug release. The result 
of in-vitro and in-vivo drug release studies indicated that formulation (drug: polymer 
=5:3), was the most successful of the study and exhibited constant and extended 
release of metformin hydrochloride 99-100.5% release at the end of 10 hours 
compared with reference standard. A decrease in release of the drug was observed on 
increasing polymer ratio at certain level. The t25%, t50% and t90% drug release values 
were calculated from selected formulation F3 on every specified period of stability 
studies and comparison of both room and accelerated condition by statistical t-test, 
there was no difference between storage temperature. The formulation F3 was showed 
similar in-vitro and in-vivo drug release when compared to market sustained release 
tablet (F5M).  
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Literature review indicating work carried out on selected drug Venlafaxine 
Hydrochloride is given below: 
 
Radhika P R.,  et al.  (2011)  was developed sustained  release  matrix  tablets  
of  Venlafaxine  Hydrochloride  using  a  high  permeable  Eudragit  RLPO  and  low 
permeable Eudragit  RSPO  in  different ratios. Tablet matrices were  prepared  by 
direct  compressionand  were  formulated  as  F1 ,F2 and F3  by using  the  above  
mentioned  polymers. Technological characterizations like thickness, diameter, 
weight variation test, drug content, hardness, and friability were carried out  with  the 
formulated  matrix  tablet .The in-vitro drug releases of the formulated tablets were 
measured using the USP -24 types II dissolution apparatus. The formulations showed 
an optimum hardness, constant weight uniformity and low friability. The kinetic 
release treatment showed that the release of drug follows Zero order  kinetic (r2 
=0.9965),   Koresmeyer equation gave value of r2= 0.9980 which was close to one 
indicating that the drug was released by Zero order kinetic. The in-vitro drug release 
data to Koresmeyer equation  indicated  that  diffusion  along  with  erosion  could  be 
the  mechanism of drug  release. The formulation F1 containing high quantity of 
Eudragit RSPO provided the slowest release profile and 90 % of the drug content was 
released after 18 hours than other formulations. The systematic formulation approach 
enabled to develop sustained release Venlafaxine Hydrochloride tablets. Further 
investigations are needed to confirm the in vivo efficacy and this study demonstrated 
that Eudragit  polymer  can  provide  controlled  release.  
 
Mukesh C. Gohel., et al. (2009)  was  developed  venlafaxine  hydrochloride-
Layered   tablets  for obtaining sustained  drug  release. The   tablets   containing  
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Venlafaxine   hydrochloride  150 mg  were  prepared  by wet  granulation technique 
Using  xanthan gum in the middle layer and barrier layers. The granules and tablets 
were  characterized. The in vitro drug dissolution study was conducted in distilled 
water.  The tablets containing two lower strengths were also developed using the same 
percentage composition of the middle layer. Kinetics of drug release was studied. The 
optimized batches were tested for water uptake study. Radar diagrams are provided to 
compare the performance of formulated tablets with the reference products, Effexor 
XR capsules. The granules ready for compression exhibited good flow and 
compressibility when xanthan gum was used in the intragranular and extragranular 
fractions. Monolayer tablets failed to give the release pattern similar to that of the 
reference product. The drug release was best explained by Weibull model. A unified 
Weibull equation was evolved to express drug release from the formulated tablets. 
Lactose facilitated drug release from barrier layers. Substantial water uptake and 
gelling of xanthan gum appears to be responsible for sustained drug release. The 
present study underlines the importance of formulation factors in achieving same drug 
release pattern from three strengths of venlafaxine hydrochloride tablets. 
            Nikil Karani  A.,  et al., (2009) have reported new, simple and cost 
effective uv-spectrophotometric method was developed for the estimation of 
venlafaxine hydrochloride in bulk and pharmaceutical formulation venlafaxine 
hydrochloride was estimated at 225.27 nm in distilled water. Linearity range was 
found to be 3.4x10
4  
mol
-1
 cm in distilled water. These methods were tested and 
validated for various parameters according to ICH guidelines and USP. The results 
demonstrated that the procedure is accurate, precise and reproducible while being 
simple, cheap and less time consuming and can be suitably applied for the estimation 
of venlafaxine hydrochloride in different dosage form and dissolution studies.  
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        Vimala Shirvi D., et al., (2010) have developed for the estimation of 
venlafaxine hydrochloride in raw material and pharmaceutical dosage form. In this 
method venlafaxine hydrochloride showed zero crossing at 274 nm, with a sharp peak 
at 285 nm. Beers law was obeyed in the concentration range of 40-120 μg/ml. The 
limit of detection and limit of quantification were found to be 1.82μg/ml and 
5.49μg/ml respectively. The method was successfully applied to the determined of 
venlafaxine hydrochloride in tablet. 
                       K. Sreenivasa rao.,  et al. (2011)  had formulated SRmatrix tablet 
using hydrophilic polymer such as HPMC, Eudragit RS100, and Ethyl cellulose as 
releases retardants. All the precompressional parameters were found to be within the 
standard limits. Tablets were evaluated for hardness, friability, thickness, drug 
content, in Vitro release, swelling and stability studies. The effect of polymer 
concentration binary polymer mixture and wet granulation method on drug release 
profile was studied. It was absorbed that the type of polymer and its concentration has 
influence the drug release from matrix tablet. Matrix tablet content a blend of HPMC 
and ethyl cellulose successfully sustained the release of Venlafaxine for a period of 
17hr. Precompressional parameter indicated that granules used preparing tablets with 
free flowing. Post-compressional parameters were withinthe acceptable limit. The 
concentration of Venlafaxine was kept constant, lactose used as filler.The sustained 
release fromethyl cellulose and HPMC was due to interaction between ethylcellulose 
chain ionic polymer and HPMC chain, non-ionic polymer, which resulted in favorable 
increase in the water uptake capacity and gel viscosity, leading to better controlover 
the release of Venlafaxine F4 showed the sustained release of Venlafaxine as desired. 
The study revealed that the ethyl cellulose and HPMC can be used for the formulation 
of sustained release matrix tablet of Venlafaxine. 
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Atul A. Bodkhe., et al.  (2010)  had formulated with Venlafaxine 
Hydrochloride equivalent to 37.5 mg of Venlafaxine base. Matrix system based on 
non swellable polymers was selected for sustaining the drug release. Different 
polymers and waxes viz. HPMC, stearic acid, cetyl alcohol, ethyl cellulose etc. were 
studied. Combinations of non swellable waxes with HPMC were also tried in order to 
get the desired sustained release profile over a period of 24 hours. The effect of drug 
to wax ratio on in-vitro release was studied. 
 
Bhalekar., et al. (2008) had formulated a sustained drug delivery system of 
Venlafaxine Hydrochloride by using a wax matrix system. The effects of bees wax 
and carnauba wax on drug release profile was investigated. A 3
2 
full factorial design 
was applied to systemically optimize the drug release profile. Amounts of carnauba 
wax (X1) and bees wax (X2) were selected as independent variables and release after 
12 hours and time required for 50% drug release were selected as dependent variables. 
A mathematical model was generated for each response parameter. Both waxes 
retarded release after 12 hours and increases the t50 but bees wax showed significant 
influence. The drug release pattern for all the formulation combinations was found to 
be approaching Peppas kinetic model. Suitable combination of two waxes provided 
fairly good related release profile. The response surfaces and contour plots for each 
response parameter are presented for further interpretation of the results. The 
optimum formulations were chosen and their predicted results found to be in close 
agreement with experimental findings.    
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S Bagdiya Om prakash.,  et al. (2011)  had developed the extended release 
formulation of Venlafaxine that releasesthe drug and maintian the plasma drug 
concentration for more than12h. Polymers like Hydroxypropylmethylcellulose 
(HPMC) K4M and K00M, NovocoatK100M,  xanthan gum, Polyox, Carbopol etc. 
Weres elected for sustaining the drug release. The tablets were prepared by direct 
compression method. In vitro drug release study revealed that Novocoat 100 Malone 
was not able to retard the drug release whereas carobopol has High potential to retard 
the drug release due to its gelling property. Kinetic modeling of in vitro drug release 
data was best fitted in Korsmeyer-Peppas equation indicates drug  releases by mixed 
mechanism of diffusion and erosion. The optimized formulation was subjected to 
stability studies at different temperature and humidity conditions as per ICH 
guidelines. 
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   5. DRUG AND EXCIPIENTS PROFILE 
 
5.1.  Drug profile: 
Venlafaxine Hydrochloride:      (The Merck Index) 
Chemical name         :       Dimethyl {5-[2-(1-methylamino-2nitrovinylamino)    
                                                     ethylthiomethyl] furfuryl}-amine hydrochloride.  
 
 Structural formula        :  
C
H3CO
H
N
OH
CH3
CH3
HCl.
 
 
 Molecular formula : C13H27NO2, HCl    
 
 Molecular weight : 313.86 
 
 Melting point                        :           215-217°C 
Drug content                          :           99-101% 
Physicochemical properties:     (www.Chemicalbook.com) 
Description                             :    White or almost white powder.  
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Solubility                                :      Freely soluble in water and methanol, insoluble  
                                                        (or) slightly soluble in acetone. 
 
Category                                 :      serotonin-norepinephrine reuptake inhibitor(SNRI)   
                                                        class 
 
Dose                                         :      75-225 mg/day (divided in 2-4 doses)  
 
Pharmacology:      (www.About CNSforum.com/venlafaxine)              
           Venlafaxine is a unique antidepressant, and is usually categorized as a 
serotonin-norepinephrine reuptake inhibitor (SNRI), but it has been referred to as a 
serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). Depression is 
associated with reduced levels of the monoamines in the brain, such as 5-HT. The 
selective 5-HT and noradrenaline re-uptake inhibitors (SNRIs) are thought to restore 
the levels of 5-HT and noradrenaline in the synaptic cleft by binding at their re-uptake 
transporters preventing the re-uptake and subsequent degradation of 5-HT and 
noradrenaline. This re-uptake blockade leads to the accumulation of monoamines in 
the synaptic cleft and the concentration returns to within the normal range. This action 
of SNRIs is though to contribute to the alleviation of the symptoms of depression. In 
the presence of the SNRIs, small amounts of 5-HT and noradrenaline continue to be 
degraded in the synaptic cleft. 
 
Pharmacokinetics:      (Goodman and Gilman, 2006) 
Absorption   :   Venlafaxine is well absorbed and extensively metabolized in the liver. 
O-desmethylvenlafaxine (ODV) is the only major active metabolite. 
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Volume of distribution   :    7.5±3.7 L/kg 
 Partition coefficient        :    octanol/water- 0.43 
 Oral bioavailability         :    10-45% 
 Plasma half life                :    5hrs. 
 Plasma protein binding    :     27% 
 
Indications:      (Tripathy K.D., 2008) 
 In endogeneous (major) depression. 
 Obsessive-compulsive and phobic states 
 Anxiety disorder 
 Neuropathic pain 
 Attention deficit-hyperactive disorder in children 
 Enuresis 
 Migraine 
 Pruritus. 
 
Adverse Effect:      (www.drugbank.ca) 
            Venlafaxine hydrochloride is generally well tolerated, with a low incidence of 
adverse effects. The most common side effects of venlafaxine are nausea, 
somnolence, headache, dry mouth, sweating, hypotension, nervousness and abnormal 
ejaculation, dizziness, insomnia, sedation and constipation. At high doses, there may 
be an increase in blood pressure.  
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 Drug Interaction:
 
 
Venlafaxine should not be used
 
with MAOIs and at least 14 days should elapse 
between stopping an MAOI and starting treatment with venlafaxine. Although the 
synergistic effects may not be as bad as with other antidepressants, it is still not 
recommended to take venlafaxine with alcohol. Venlafaxine may lower the seizure 
threshold, and co administration with other drugs that lower the seizure threshold such 
as bupropion and tramadol should be done with caution and at low doses. Although 
cimetidine inhibits the hepatic metabolism of venlafaxine, it has no effect on the 
active metabolite of venlafaxine, o-desmethylvenlafaxine 
  
 Dosage Forms:      ( http://en.wikipedia.org/wiki/Venlafaxine)                                                                                 
 Tablets            : 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg and 225mg. 
 Tablet             : ER-   37.5 mg, 75 mg, and 150 mg and 225mg. 
 Capsules ER : 7.5 mg (gray/peach), 75 mg (peach), and 150 mg (brownish 
red).
   
 
 
 Contraindications: 
                         Venlafaxine is not recommended in patient with hypersensitive,
 
Glaucoma, Pregnant women, 
  
Heart disease and hypertension.
  
It should never be used 
with a monoamine oxidase inhibitor (MAOI), as it can cause potentially fatal 
serotonin syndrome. Caution should also be used in those with a seizure disorder. 
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5.2. Excipients profile:                                     
5.2.1. Carnauba wax:     (Raymond C. R., et al., 2009) 
Nonproprietary names: 
             BP      : Carnauba Wax 
             JP       : Carnauba Wax 
            PhEur  : Carnauba Wax 
            USP-NF : Carnauba Wax 
 
Synonyms: 
          Brazil wax; caranda wax; cera carnauba. 
 
Chemical name and CAS registry number:  
                Carnauba wax [8015-86-9] 
 
Functional category:  
               Coating agent. 
 
Applications in pharmaceutical formulation or technology: 
                   Carnauba wax  is   widely  used  in  cosmetics,  certain  foods,  and 
Pharmaceutical  formulations. Cosmetically, carnauba  wax  is commonly used  in  lip  
balms. 
                   Carnauba wax  is  the  hardest  and  highest-melting  of  the  waxes 
commonly  used  in  pharmaceutical  formulations   and   is   used primarily  as  a   
10% w/v aqueous  emulsion  to  polish  sugar-coated tablets. Aqueous emulsions may    
Venlafaxine Sustained Release Matrix Tablets    DRUG AND EXCIPIENTS PROFILE 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  67 
 
be  prepared  by  mixing  carnauba wax  with  an  ethanolamine  compound  and  oleic 
acid. The carnauba wax  coating  produces  tablets  of  good  luster  without rubbing. 
Carnauba wax may also be used in powder form to polish sugarcoated tablets. 
                   Carnauba wax (10–50% w/w)  is  also  used  alone  or  with  other 
excipients  such  as  hypromellose,  hydroxypropyl  cellulose,  alginate/ pectin-gelatin,  
Eudragit,  and  stearyl  alcohol  to  produce  sustained release solid-dosage  
formulations. 
                   Carnauba  wax  has  been  experimentally  investigated  for  use  in 
producing   microparticles  in  a  novel  hot  air  coating (HAC)  process developed  as  
an  alternative  to  conventional  spray-congealing  techniques. In addition,  carnauba  
wax  has  been used  to  produce  gel  beads  for  intragastric floating  drug  delivery  
and  has  been  investigated  for  use  in  nanoparticulate sunscreen  formulations. 
 
Description:  
                          Carnauba  wax  occurs  as  a  light brown -  to  pale  yellow – colored  
powder,  flakes,  or  irregular  lumps  of  a  hard,  brittle  wax.  It  has  a characteristic  
bland  odor  and  practically  no  taste.  It  is  free  from rancidity. Various types and 
grades  are  available  commercially. 
 
Melting point:  
      80–88°C 
 
Solubility: 
       Soluble  in  warm  chloroform  and  in  warm  toluene;  slightly  soluble in  
boiling  ethanol (95%);  practically  insoluble  in water  
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Stability and storage conditions:  
                Carnauba wax  is  stable  and  should  be  stored  in  a  well-closed 
container,  in  a  cool,  dry place. 
 
5.2.2. Cetyl alcohol:      (Raymond C. R., et al., 2009) 
Nonproprietary names:  
                 BP      : Cetyl Alcohol 
                 JP       : Cetanol 
               PhEur   : Cetyl Alcohol 
               USP-NF   : Cetyl Alcohol 
 
Synonyms:  
                  Alcohol  cetylicus;  Avol;  Cachalot;  Crodacol C70;  Crodacol C90; 
Crodacol C95;  ethal;  ethol;  HallStar CO-1695;  1-hexadecanol;  nhexadecyl alcohol;  
Hyfatol 16-95;   Hyfatol 16-98;   Kessco CA;  Lanette 16;  Lipocol C;  Nacol   16-95;  
palmityl alcohol; Rita CA;  Speziol C16 Pharma;  Tego Alkanol 16;  Vegarol   1695. 
 
Structural formula:  
                                   
 
Chemical name and CAS registry number: 
               Hexadecan-1-ol [36653-82-4]  
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Description:    
               Cetyl alcohol occurs as waxy, white flakes, granules, cubes, or castings.  It 
has a faint characteristic odor and bland taste. 
 
Melting point: 
                 45-52°C 
 
Empirical formula and molecular weight:   
 C16H34O 242.44 (for pure material)  
Cetyl alcohol, used in pharmaceutical preparations, is a mixture of solid 
aliphatic alcohols comprising mainly 1-hexadecanol (C16H34O). The USP32–NF27 
specifies not less than 90.0% of cetyl alcohol, the remainder consisting chiefly of 
related alcohols. Commercially, many grades of cetyl alcohol are available as 
mixtures of cetyl alcohol (60–70%) and stearyl alcohol  (2030%), the remainder being 
related alcohols. 
 
Functional Category:  
                Coating agent; emulsifying agent; stiffening agent.                                                                
 
Solubility:  
                 Freely soluble in ethanol (95%) and ether, solubility increasing with 
increasing temperature; practically insoluble in water. Miscible when melted with 
fats, liquid and solid paraffins, and isopropyl myristate. 
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Applications in pharmaceutical formulation or technology:  
                  Cetyl alcohol is widely used in cosmetics and pharmaceutical formulations 
such as suppositories, modified-release solid dosage forms, emulsions, lotions, 
creams, and ointments. In suppositories cetyl alcohol is used to raise the melting point 
of the base, and in modified-release dosage forms it may be used to form a permeable 
barrier coating. In lotions, creams, and ointments cetyl alcohol is used because of its 
emollient, water-absorptive, and emulsifying properties. It enhances stability, 
improves texture, and increases consistency. The emollient properties are due to 
absorption and retention of cetyl alcohol in the epidermis, where it lubricates and 
softens the skin while imparting a characteristic „velvety‟ texture. 
                  Cetyl alcohol is also used for its water absorption properties in water-in-oil 
emulsions. For example, a mixture of petrolatum and cetyl alcohol (19 : 1) will absorb 
40–50% of its weight of water. 
                 Cetyl alcohol acts as a weak emulsifier of the water-in-oil type, thus 
allowing a reduction of the quantity of other emulsifying agents used in a formulation. 
Cetyl alcohol has also been reported to increase the consistency of water-in-oil 
emulsions. In oil-in-water emulsions, cetyl alcohol is reported to improve stability by 
combining with the water-soluble emulsifying agent. The combined mixed emulsifier 
produces a close packed, monomolecular barrier at the oil–water interface which 
forms a mechanical barrier against droplet coalescence. 
                 In semisolid emulsions, excess cetyl alcohol combines with the aqueous 
emulsifier solution to form a viscoelastic continuous phase that imparts semisolid 
properties to the emulsion and also prevents droplet coalescence. Therefore, cetyl 
alcohol is sometimes referred to as a „consistency improver‟ or a „bodying agent‟, 
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although it may be necessary to mix cetyl alcohol with a hydrophilic emulsifier to 
impart this property. 
It should be noted that pure or pharmacopeial grades of cetyl alcohol may not 
form stable semisolid emulsions and may not show the same physical properties as 
grades of cetyl alcohol that contain significant amounts of other similar alcohols.  
 
Stability and Storage conditions: 
                Cetyl alcohol is stable in the presence of acids, alkalis, light, and air; it does 
not become rancid. It should be stored in a well-closed container in a cool, dry place.  
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5.2.3.Stearic acid:      (Raymond C. R., et al., 2009) 
Nonproprietary names:  
BP      : Stearic Acid 
JP      : Stearic Acid 
PhEur   : Stearic Acid 
USP-NF : Stearic Acid 
 
Synonyms:  
Acidum stearicum; cetylacetic acid; Crodacid; Cristal G; Cristal S; Dervacid; 
E570; Edenor; Emersol; Extra AS; Extra P; Extra S; Extra ST; 1-hepta decane 
carboxylic acid; Hystrene; Industrene; Kortacid 1895; Pearl Steric; Pristerene; 
stereophanic acid; Tegostearic. 
 
Structural formula:  
                       
 
Chemical name and CAS registry number:  
Octadecanoic acid [57-11-4] 
 
Description:  
                Stearic acid is a hard, white or faintly yellow-colored, somewhat glossy, 
crystalline solid or a white or yellowish white powder. It has a slight odor (with an 
odor threshold of 20 ppm) and taste suggesting tallow. 
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Melting point: 
                   66-69°C 
 
Empirical formula and molecular weight: 
C18H36O2 284.47 (for pure material) 
The USP32–NF27 describes stearic acid as a mixture of stearic acid 
(C18H36O2) and palmitic acid (C16H32O2). In the USP32– NF27, the content of stearic 
acid is not less than 40.0% and the sum of the two acids is not less than 90.0%.  
The USP32–NF27 also contains a monograph for purified stearic acid; The 
PhEur 6.5 contains a single monograph for stearic acid but defines stearic acid 50, 
stearic acid 70, and stearic acid 95 as containing specific amounts of stearic acid 
(C18H36O2). 
 
Functional Category:  
Emulsifying agent; solubilizing agent; tablet and capsule lubricant                                                                                                                                               
 
Applications in pharmaceutical formulation or technology:  
Stearic acid is widely used in oral and topical pharmaceutical formulations. It 
is mainly used in oral formulations as a tablet and capsule lubricant; although it may 
also be used as a binder or in combination with shellac as a tablet coating. It has also 
been suggested that stearic acid may be used in enteric tablet coatings and as a 
sustained-release drug carrier. In topical formulations, stearic acid is used as an 
emulsifying and solubilizing agent. When partially neutralized with alkalis or 
triethanolamine, stearic acid is used in the preparation of creams. The partially 
neutralized stearic acid forms a creamy base when mixed with 5–15 times its own 
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weight of aqueous liquid, the appearance and plasticity of the cream being determined 
by the proportion of alkali used. 
          Stearic acid is used as the hardening agent in glycerin suppositories.  Stearic 
acid is also widely used in cosmetics and food products. 
 
Stability and storage: 
Stearic acid is a stable material; an antioxidant may also be added to it. The 
bulk material should be stored in a wellclosed container in a cool, dry place.   
    
5.2.4. Lactose:      (Raymond C. R., et al., 2009) 
Nonproprietary names:  
BP     : Lactose 
PhEur   : Lactose Monohydrate 
JP     :  Lactose Hydrate  
USP   : Lactose Monohydrate 
 
Synonyms:  
CapsuLac; GranuLac; Lactochem; lactosum monohydricum; Monohydrate; 
Pharmatose; PrismaLac; SacheLac; SorboLac; SpheroLac; SuperTab 30GR; 
Tablettose. 
 
Chemical name and CAS registry number:  
                O-b-D-Galactopyranosyl-(1!4)-a-D-glucopyranose monohydrate [5989-81-
1]; [10039-26-6]; [64044-51-5] CAS Registry numbers for lactose monohydrate are 
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[5989-81- 1] (lactose monohydrate), [10039-26-6] (lactose monohydrate, cyclic), and 
[64044-51-5] (lactose monohydrate, open form). 
 
Structural formula:          
                              
 
Empirical Formula and Molecular Weight: 
                  C12H22O11_H2O   360.31 
 
Functional category:  
Dry powder inhaler carrier; lyophilization aid; tablet binder; tablet and capsule 
diluent; tablet and capsule filler. 
 
Description:  
In the solid state, lactose appears as various isomeric forms, depending on the 
crystallization and drying conditions, i.e. alactose monohydrate, b-lactose anhydrous, 
and a-lactose anhydrous. 
The stable crystalline forms of lactose are a-lactose monohydrate, b-lactose 
anhydrous, and stable a-lactose anhydrous. Lactose occurs as white to off-white 
crystalline particles or powder. Lactose is odorless and slightly sweet-tasting; a-
lactose is approximately 20% as sweet as sucrose, while b-lactose is 40% as sweet. 
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Moisture content:  
Lactose monohydrate contains approximately 5% w/w water of  crystallization 
and normally has a range of 4.5–5.5% w/w water content. 
 
Applications in pharmaceutical formulation or technology:  
Lactose is widely used as a filler and diluent in tablets and capsules, and to a 
more limited extent in lyophilized products and infant formulas.(1–9) Lactose is also 
used as a diluent in dry-powder inhalation; seeLactose, Inhalation. Various lactose 
grades are commercially available that have different physical properties such as 
particle size distribution and flow characteristics. This permits the selection of the 
most suitable material for a particular application; for example, the particle size range 
selected for capsules is often dependent on the type of encapsulating machine used. 
                 364 Lactose, Monohydrate Usually, fine grades of lactose are used in the 
preparation of tablets by the wet-granulation method or when milling during 
processing is carried out, since the fine size allows better mixing with other 
formulation ingredients and utilizes the binder more efficiently. 
               Other applications of lactose include use in lyophilized products, where 
lactose is added to freeze-dried solutions to increase plug size and aid cohesion. 
Lactose is also used in combination with sucrose (approximately 1 : 3) to prepare 
sugar-coating solutions. It may also be used in intravenous injections. 
                 Lactose is also used in the manufacture of dry powder formulations for use 
as aqueous film-coating solutions or suspensions. Direct-compression grades of 
lactose monohydrate are available as granulated/agglomerated a-lactose monohydrate, 
containing small amounts of anhydrous lactose. Direct-compression grades are often 
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used to carry lower quantities of drug and this permits tablets to be made without 
granulation.  
 
Stability and storage conditions:  
Mold growth may occur under humid conditions (80% relative humidity and 
above). Lactose may develop a brown coloration on storage, the reaction being 
accelerated by warm, damp conditions; The purities of different lactoses can vary and 
color evaluation may be important, particularly if white tablets are being formulated. 
The color stabilities of various lactoses also differ. Solutions show mutarotation;  
Lactose should be stored in a well-closed container in a cool, dry place. 
 
5.2.5. Talc:     (Raymond C. R., et al., 2009) 
Nonproprietary names: 
BP : Purified talc 
JP : Talc 
PhEur : Talcum 
USPNF : Talc 
 
Synonyms: 
 Purified chalk, altalc, powdered talc and soapstone 
 
Chemical name and CAS registry number: 
Talc [14807-96-6] 
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Description: 
            A very fine, white to grayish white, impalpable, odorless crystalline powder,  
Unctuous, adheres readily to skin, soft to touch and free from granules. 
 
Empirical formula:   
 Mg6 (Si2O5)4(OH)4 
 
Functional category: 
            Tablet, capsule it can use as a lubricant and diluents. During compression used 
as glidant and anticaking agent. 
 
Solubility:    
 Insoluble in water, organic solvents, dilutes acids and alkalis. 
 
Storage conditions:  
 Stable, Preserve in a well-closed container in a cool, dry place. 
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                       6. MATERIALS AND EQUIPMENTS 
 
6.1. Materials used: 
Table 6.1: List of materials with source 
S.No. Name of Ingredients Name of supplier 
1 
Venlafaxine 
Hydrochloride 
Orchid pharmaceuticals, Puducherry. 
2 Carnauba wax Shasun pharmaceuticals, Puducherry. 
3 Cetyl alcohol Tristar formulations Pvt. Ltd., Puducherry. 
4 Stearic acid Tristar formulations Pvt. Ltd., Puducherry. 
5 Lactose Loba chemie Pvt.Ltd., Mumbai. 
6 Talc Loba chemie Pvt.Ltd., Mumbai. 
7 Hydrochloric acid S d fine-chem limited, Mumbai. 
8 Methanol Qualigens fine chemicals, Mumbai. 
9 Acetone Loba chemie Pvt.Ltd., Mumbai. 
10 Sodium hydroxide S d fine-chem limited, Mumbai. 
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6.2. Equipments used: 
Table 6.2: List of equipments with model/make 
S.No. Equipment Model/ Make 
1 Electronic balance Shimadzu BL-220H, Japan. 
2 Bulk density apparatus Indolabs VTAP/MATIC-II, Chennai. 
3 Standard sieves Jayant scientific, India. 
4 Hot air oven Precision scientific Co., Chennai. 
5 
Sixteen punch tablet compression 
machine 
Cadmach, Ahmadabad, India. 
6 Friability apparatus Veego scientific VFT-DV, Mumbai. 
7 Hardness tester Monsanto 
8 Vernier caliper Indolabs, Mitutoyo. 
9 Humidity chamber Labtech, Ambala. 
10 
USP dissolution test apparatus 
Type I 
Veego scientific VDA-8DR, Mumbai. 
11 UV-Visible spectrophotometer 
Elico-SL 159 UV-Visible 
spectrophotometer, Japan. 
12 FTIR spectrophotometer Shimadzu, Japan. 
13 Differential scanning calorimeter Shimadzu, Japan. 
 
 
 
 
  
 
 
EXPERIMENTAL 
WORK 
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7. EXPERIMENTAL WORK 
 
7.1. Preformulation study: 
 Preformulation testing is an investigation of physical and chemical properties 
of a drug substance alone. It is the first step in rational development of dosage form. 
 
7.1.1. Identification of drug: 
7.1.1.1. Identification by FTIR spectroscopy:     (IP, 2007; Skoog D.A., et al., 2004)     
 Venlafaxine Hydrochloride discs were prepared by pressing the Venlafaxine 
Hydrochloride with potassium bromide and the spectra ranges between 4000 to 400 
cm
-1
 was obtained under the operational conditions. The absorption maximums in 
spectrum obtained with the substance being examined correspond in position and 
relative intensity to those in the reference spectrum.  
 
7.1.1.2. Identification by melting point:     (IP, 2007)                                                
 
Melting point of the drug was determined by capillary tube method. 
 
7.1.2. Physicochemical parameters:
 
7.1.2.1. Organoleptic properties:     (Lachman L., et al., 1991; Banker G.S. and 
Rhodes C.T., 1996)   
The color, odor and taste of the drug were recorded using descriptive 
terminology. 
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7.1.2.2. Solubility study:     (IP, 2007)
 
           It is important to know about solubility characteristic of a drug in aqueous 
system, since they must possess some limited aqueous solubility to elicit a therapeutic 
response. The solubility of drug was recorded by using various descriptive 
terminology specified in Indian Pharmacopoeia, 2007.  
 
7.1.2.3. Loss on drying:     (IP, 2007)
 
 
 
          Loss on drying was the loss of weight expressed as percentage w/w resulting 
from water and volatile matter of any kind that can be driven off under specified 
condition. The accurately weighed 1gm of sample was transferred in glass-stoppered, 
shallow weighing bottle and accurately weighed the bottle. The bottle was transferred 
in oven and substance was dried at 105°C for 3 hours. The bottle was removed from 
oven and reweighed; loss on drying was calculated by following equation,
 
 
 
 
7.1.3. Analytical methods:  
7.1.3.1. . Determination of λ max:     (Patil Prakash., et al., 2011)                                                                                                                    
The absorption maximum of the standard solution was scanned between 200-
400 nm regions on Shimadzu-1700 Pharmaspec UV-Visible spectrophotometer. The 
absorption maximum obtained with the substance being examined corresponds in 
position and relative intensity to those in the reference spectrum.                                                                                                                  
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7.1.3.2. Preparation of standard curve of Venlafaxine Hydrochloride  in 0.1N 
HCl:     ( Patil Prakash., et al., 2011)  
            A stock solution of Venlafaxine Hydrochloride was prepared by dissolving 
100 mg of drug in 0.1 N HCl and final volume was made to 100 ml to give a solution 
concentration 1000 µg/ml. From the stock solution, 10 ml was pipettted out into 100 
ml volumetric flask to obtain concentration of 100µg/ml. From the standard stock 
solution of Venlafaxine Hydrochloride, appropriate aliquots of 1, 2, 3, 4  and 5 ml 
were pipetted out into 25 ml volumetric flask and final volume was made with 0.1 N 
HCl. To obtained concentration of 4, 8, 12, 16  and 20 µg/ml. Absorbance spectra of 
each solution against 0.1 N HCl as blank were measured at 225.5 nm using Elico-SL 
159 UV-Visible spectrophotometer.   
 
7.1.3.4. Preparation of standard curve of Venlafaxine Hydrochloride in pH 6.8 
phosphate buffer:     ( Patil Prakash., et al., 2011) 
            A stock solution of Venlafaxine Hydrochloride was prepared by dissolving 
100 mg of drug in pH 6.8 and final volume was made to 100 ml to give a solution 
concentration 1000 µg/ml. From the stock solution, 10 ml was pipettted out into 100 
ml volumetric flask to obtain concentration of 100µg/ml. From the standard stock 
solution of Venlafaxine Hydrochloride appropriate aliquots of 1, 2, 3, 4 and 5 ml were 
pipetted out into 50 ml volumetric flask and final volume was made with pH 6.8. To 
obtained concentration of 4, 8, 12, 16 and 20 µg/ml. Absorbance spectra of each 
solution against pH 6.8 as blank were measured at 226 nm using Elico-SL 159 UV-
Visible spectrophotometer.  
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 7.1.3.5. Determination of Percentage purity of Drug:     ( Patil Prakash., et al., 
2011)    
Accurately weighed 100 mg of Venlafaxine Hydrochloride was dissolved in 
little quantity of pH 6.8 Phosphate buffer and volume was adjusted to 100 ml with the 
same to prepared standard solution having concentration of 1000 µg/ml. From the 
above solution, aliquots of 5 ml were transferred to 25 ml volumetric flasks and final 
volume was made up to 25 ml with pH 6.8. Absorbance values of these solutions were 
measured against blank (pH 6.8) at 225.5 nm using UV-VISIBLE spectrophotometer. 
The percentage purity of drug was calculated by using calibration graph method (least 
square method).  
 
7.1.4. Determination of drug-polymer compatibility:     (Aulton M.E., 2007) 
 Differential scanning calorimetry, Fourier transforms infrared spectroscopy 
studies were used for the evaluation of physicochemical compatibility and  
interaction, which helps in the prediction of interaction of the drug and polymers. 
Each polymer used in the formulations was blended with the drug levels that are 
realistic with respect to the final dosage form. Each polymer was thoroughly blended 
with drug to increase drug- polymer molecular contacts to accelerate the reactions if 
possible. 
 
7.1.4.1. Fourier transform infrared spectroscopy:    (Bhalekar., et al., 2008; 
Jadhav Sunita.,et al., 2011; Silverstein R.M., 2003)         
            FTIR studies are very helpful in the evaluation of drug polymer interaction 
studies. If there is any incompatibility between the drug and polymer, these can be 
predicted by changes in the functional peaks. Infrared spectrum of Venlafaxine 
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Hydrochloride was determined on Fourier transform infrared spectrophotometer using 
potassium bromide dispersion method. The base line correction was done using dried 
potassium bromide. Then the spectrum of dried mixture of drug and various polymers 
were thoroughly mixed with potassium bromide. The crushed powders were 
compressed using a hydraulic compactor at approximately 20,000 pounds under 
vacuum for 3 minutes. FTIR instrument were performed under nitrogen atmosphere at 
a flow rate of 50 standard cubic feet per hour. Spectral scanning was conducted from 
4000 to 400 cm
-1
 at a resolution of 4 cm
-1
 by using Shimadzu (Japan) FTIR 
spectrophotometer.  
 
7.1.4.2. Differential scanning calorimetry:     (Atul A. Bodkhe.,et al., 2010) 
            Any possible drug polymer interaction can be studied by thermal analysis. The 
DSC analysis of pure drug, drug with carnauba wax  were carried out using Shimadzu 
to evaluate any possible drug-polymer interaction. The 2 mg sample were heated in a 
hermetically sealed aluminum pans in the temperature range of 25-300ºC at heating 
rate of 10ºC /min under nitrogen flow of 30 ml/min.  
 
7.1.5. Formulation of Venlafaxine Hydrochloride sustained release matrix 
tablets:     (Bhalekar., et al., 2008)                                                
  All the ingredients mentioned in Table 7.1 were pre-weighed and passed the 
drug through mesh #80. The waxes were molten and then required quantity of drug 
was slowly added to the molten wax. After cooling, the mass was subjected to 
granulation by passing through mesh #16. Granules were mixed with lactose and talc 
and also used for evaluation of flow characteristic. 
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                   Table 7.1: Composition of Venlafaxine Hydrochloride SR matrix tablets 
Ingredients VF1 VF2 VF3 VF4 VF5 VF6 VF7 VF8 VF9 
Venlafaxine 
Hydrochloride 
75 75 75 75 75 75 75 75 75 
Carnauba wax 53 106 159 - - - - - - 
Cetyl alcohol - - - 53 106 159 - - - 
Stearic acid - - - - - - 53 106 159 
Lactose 204 151 98 204 151 98 204 151 98 
Talc 18 18 18 18 18 18 18 18 18 
Total weight 350 350 350 350 350 350 350 350 350 
                              
                All the quantities are expressed as mg per tablet. 
 
7.1.6. Evaluation of pre-compression granules: 
7.1.6.1. Angle of repose:     (Lachman L., et al., 1991) 
The angle of repose was determined by the funnel method. An accurately 
weighed powder was taken in a funnel. The height of the funnel was adjusted in such 
a way that the tip of the funnel just touched the apex of the heap of the powder. The 
powder was allowed to flow through the funnel freely onto the surface. The diameter 
of the powder cone was measured. The angle of repose was calculated using the 
following equation. 
 
Where „h‟ and „r‟ are the height and radius respectively of the powder cone. 
 Venlafaxine sustained Release Matrix Tablets                    EXPERIMENTAL WORK 
   
Adhiparasakthi College of Pharmacy, Melmaruvathur.  88 
 
                            Table 7.2: Standard values of angle of repose (°) 
S. No. Flowability  Angle of repose  
1 Excellent <25 
2 Good 25-30 
3 Passable* 30-40 
4 Poor 37-45 
5 Very poor >45 
                            * Adding glidant for improving flow 
 
7.1.6.2. Loose bulk density:     (Lachman L., et al., 1991)
 
An accurately weighed powder blend from each formula was lightly shaken to 
break any agglomerates formed and it was introduced in to a measuring cylinder. The 
volume occupied by the powder was measured which gave bulk volume. The loose 
bulk density of powder blends was determined using the following formula. 
Loose bulk density = Total weight of powder / Total volume of powder 
 
7.1.6.3. Tapped bulk density:     (Lachman L., et al., 1991) 
An accurately weighed powder blend from each formula was lightly shaken to 
break any agglomerates formed and it was introduced into a measuring cylinder. The 
measuring cylinder was tapped until no further change in volume was noted which 
gave the tapped volume. The tapped bulk densities of powder blends were determined 
using the following formula. 
   Tapped bulk density= Total weight of powder / Total volume of tapped powder 
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7.1.6.4. Hausner’s ratio:     (Aulton M.E., 2007) 
It is related to interparticulate friction and could be used to predict powder 
flow properties.   Hausner‟s ratio was determined by following equation,    
Hausner’s Ratio = Tapped bulk density / Loose bulk density 
  A Hausner ratio less than 1.25 indicates good flow while greater than 1.5 
indicates poor flow. 
 
7.1.6.5. Carr’s compressibility index:     (Aulton M.E., 2007) 
It is a simple index that can be determined on small quantities of powder. The 
compressibility indices of the powder blends was determined using following 
formula, 
     Carr’s compressibility index (%) = [(TBD-LBD)/ TBD] x100 
Relationship between % compressibility and flowability is shown in the table 7.3.  
                             Table 7.3: Standard values of Carr‟s index 
S. No. Carr’s index Type of flow 
1 5-15 Excellent 
2 12-16 Good 
3 18-21 Fair to passable 
4 23-35 Poor* 
5 33-38 Very poor* 
6 >40 Extremely poor* 
                  * May be improved by glidant 
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7.2. Preparation of SR Matrix Tablets:      (Atul A. Bodkhe., et al., 2010)  
Hot melt granulation method: 
All the ingredients metioned in Table 7.1 were pre-weighed and passed the 
drug through mesh #80. The waxes were molten and then required quantity of drug 
was slowly added to the molten wax. After cooling, the mass was subjected to 
granulation by passing through mesh #16. Granules were mixed with lactose and talc 
and compressed on a 16- station rotary tablet compression machine using 11mm 
round, biconcave punches.   
The drug polymer ratio was developed to adjust drug release as per theoretical 
release profile and to keep total weight of tablet constant for all the fabricated batches 
under experimental conditions of preparations. The total weight of the matrix tablets 
was 350 mg with different drug polymer ratios like 1:0.7, 1:1.4, and 1:2.1. The 
various polymers used were carnauba wax, cetyl alcohol and stearic acid. 
In the formulations prepared, the release retardants included were carnauba 
wax, cetyl alcohol and stearic acid. Lactose is used as diluent and talc 5 % were used 
as lubricant and glidant.  
 
7.3. Evaluation of Venlafaxine Hydrochloride sustained release matrix tablets:  
 
7.3.1. Appearance:     (Lachman L., et al., 1991) 
The tablets were visually observed for capping, chipping and lamination. 
 
7.3.2. Dimension (Thickness and Diameter):     (Lachman L., et al., 1991)                          
 The thickness and diameter of tablets were important for uniformity of tablet 
size. The thickness and diameter of the tablets was determined by using Vernier 
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caliper. Ten tablets from each type of formulation were used and average values were 
calculated.  
 
7.3.3. Tablet hardness:     (Lachman L., et al., 1991) 
For each formulation, the hardness of 10 tablets was determined using the 
Monsanto hardness tester. The tablet was held along its oblong axis in between the 
two jaws of the tester. At this point, reading should be zero kg/cm
2
. Then constant 
force was applied by rotating the knob until the tablet fractured. The value at this 
point was noted in kg/cm
2
.  
 
7.3.4. Percent friability:     (Lachman L., et al., 1991) 
Friability is the measure of tablet strength. This test subjects a number of 
tablets to the combined effect of shock abrasion by utilizing a plastic chamber which 
revolves at a speed of 25 rpm, dropping the tablets to a distance of 6 inches in each 
revolution. A sample of pre weighed tablets was placed in Roche friabilator which 
was then operated for 100 revolutions. The tablets were then dedusted and reweighed. 
A loss of less than 1 % in weight is generally considered acceptable. Percent friability 
(% F) was calculated as follows.  
 
 
7.3.5. Weight variation:     (IP, 2007; Lachman L., et al., 1991) 
To find out weight variation 20 tablets of each formulation were weighed 
individually using an electronic balance, average weight was calculated and 
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individual tablet weight was then compared with average value to find the deviation 
in weight. The test was performed according to the official method. 
Weight variation importance during tablets compression section, each and 
every time intervals we must check the weight of tablet. If we are not maintaining the 
weight variation means it will give the deviation of drug content as well as yield of 
tablets.  
Table 7.4: Specifications of % weight variation allowed in tablets as per 
Indian Pharmacopoeia 
S. No. Average weight of tablets (mg) 
Maximum percent deviation 
allowed (%) 
1 80 or less 10 
2 More than 80 but less than 250 7.5 
3 More than 250 5 
 
7.3.6. Drug content:     ( Patil Prakash., et al., 2011)    
                The drug content in each formulation was determined by triturating 20 
tablets and powder equivalent to 100 mg of Venlafaxine Hydrochloride was 
transferred into a 100 ml standard volumetric flask. Then added 50ml of pH 6.8 
phosphate buffer solution. It was gently shaken for 15 minutes. Then made upto the 
mark with pH 6.8 phosphate buffer solution. The solution was filtered through a 
whatmann filter paper, diluted suitably and the absorbance of resultant solution was 
measured by using Elico-SL 159 UV-Visible spectrophotometer at 226nm using pH 
6.8 phosphate buffer as blank. 
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7.3.7. In vitro release studies:     (Atul A. Bodkhe., et al., 2010)                                   
The release rate of Venlafaxine Hydrochloride from matrix tablets was 
determined using United States Pharmacopoeia dissolution testing apparatus I (Basket 
method; Veego Scientific VDA-8DR, Mumbai, India). The dissolution test was 
performed at 50 rpm using 900 ml of pH 1.2  for the first 2 hrs and phosphate buffer 
pH 6.8 from 2-10 hrs at 37 ± 0.5°C. A sample (5 ml) of the solution was withdrawn 
from the dissolution apparatus hourly and the samples were replaced with fresh 
dissolution medium. The samples were filtered through a 0.45μ membrane filter and 
diluted suitably. Absorbance of these solutions was measured at 226 nm using Elico-
SL 159 UV-Visible spectrophotometer. For each formulation, the experiments were 
carried out in triplicate. The release data were analyzed to study the release kinetics 
using zero order, first order and matrix, korsmeyer-peppas equations by using PCP 
disso V3 software. 
 
7.3.8. Kinetics of in vitro drug release:     (Brahmankar D.M. and Jaiswal S.B., 
2009; Mukesh C. Gohel., et al., 2012) 
To study the release kinetics of in vitro drug release, the data was applied to 
kinetic models such as zero order, first order, higuchi and korsmeyer- Peppas. 
 Zero order 
 
Where     K0 - Zero-order rate constant expressed in units of concentration/time   
                 t - Time in hrs. 
  
C = K0t                                                                                                               
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 First order 
 
Where   C0 - Initial concentration of drug, 
               K - First order constant and t - Time in hrs.  
 Higuchi 
 
Where   Qt - Amount of the release drug in time t, 
               K- Kinetic constant and t- is time in hrs 
 Korsmeyer Peppas 
 
Where, Mt - represents amount of the released drug at time t,  
           M∞- Overall amount of the drug (whole dose) released after 12 hrs  
           K- Diffusion characteristic of drug/ polymer system constant  
           n- Diffusion exponent that characterizes the mechanism of release of drug.  
 
Table 7.5: Diffusion exponent and solute release mechanism 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n <0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n>0.89 Super case-II transport 
 
  
LogC = LogC0 – Kt / 2.303                                                                             
Qt = Kt
1/2
                                                                                                          
Mt / M∞ = Kt n                                                                                                                                                                                                    
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7.4. Stability study:     (Atul A. Bodkhe., et al., 2010)                                        
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted.  
ICH specifies the length of study and storage conditions 
 Long-Term Testing: 25 C ± 2 C at 60% RH ± 5% for 12 Months  
 Accelerated Testing: 40 C ± 2 C at 75% RH ± 5% for 6 Months  
In present study the selected formulation VF3 exposure  up to 3 months 
stability studies at accelerated condition (40 C ± 2 C
 
at 75% RH ± 5% RH) to find 
out the effect of aging on hardness, friability, drug content and in vitro drug release.  
Stability studies were carried out at accelerated condition (40 C ± 2 C
                    
at 75% RH ± 5% RH) for the optimized formulation VF3. The matrix                  
tablets were stored at 40 C ± 2 C at 75% RH ± 5% RH for accelerated         
temperature in closely packed with aluminium foil for 3 months. The                
samples were withdrawn after periods of 1
st
 month, 2
nd
 month and 3
rd
 month. The 
samples were analyzed for its hardness, drug content and in vitro drug release.   
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                        8. RESULTS AND DISCUSSION 
 
8.1. Preformulation parameters: 
8.1.1. Identification of drug: 
8.1.1.1. Identification by FTIR spectroscopy: 
The FTIR spectrum of Venlafaxine Hydrochloride was shown in Figure 8.1 
and the interpretations of FTIR frequencies were showed in Table 8.1. 
 
 Figure 8.1: FTIR spectrum of Venlafaxine Hydrochloride 
 
 Interpretation of FTIR Spectrum: 
Major functional groups present in Venlafaxine Hydrochloride shows 
characteristic peaks in FTIR spectrum. Table 8.1 shows peaks observed at different 
wave numbers and the functional group associated with these peaks.
 
The major peaks 
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are identical to functional group of Venlafaxine Hydrochloride. Hence, the sample 
was confirmed as Venlafaxine Hydrochloride. 
 
Table 8.1: Characteristic frequencies in  
FTIR spectrum of Venlafaxine Hydrochloride 
Wave No.(cm
-1
) Inference 
3015.28 C-H stretching 
2935.16 R-O-CH3 stretching 
1318.13 NH2 stretching 
1153.44 OH stretching 
1042.48 CH2 stretching 
836.68 C-H bending 
740.09 OH bending 
  
8.1.1.2. Melting point: 
Melting point of Venlafaxine Hydrochloride sample was found to be 216
0
C. 
The reported melting point for Venlafaxine Hydrochloride was in range of 215 to 
217
0
C. Hence, experimental values are in good agreement with official values. 
 
8.1.2. Physicochemical parameters of drug: 
8.1.2.1. Organoleptic properties: 
Colour:  White or almost white powder 
Odour:  Odourless 
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8.1.2.2. Solubility study: 
Table 8.2: Solubility of Venlafaxine Hydrochloride in different solvents 
 
8.1.2.3. Loss on drying  
The percentage loss on drying after 3 hours was represented in Table 8.3. 
          Table 8.3: Percentage loss on drying for Venlafaxine Hydrochloride 
 
The sample passes test for loss on drying as per the limit specified 
(N.M.T.1%). 
 
  
Name of solvents Solubility 
Distilled water Freely Soluble 
Methanol Freely Soluble 
Acetone Sparingly Soluble 
Phosphate buffer (pH 6.8) Soluble 
0.1N HCl Soluble 
S. No. Percentage  LOD Average percentage LOD 
1 0.107  
0.107 
 
2 0.112 
3 0.104 
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8.1.3. Analytical methods:
 
8.1.3.1. Determination of absorption maximum in 0.1 N HCl: 
                  The absorption maximum for Venlafaxine Hydrochloride in 0.1N 
HCL was found to be 225.5 nm and absorption maximum was shown in Figure 8.2. 
 
Figure 8.2: λ max observed for Venlafaxine Hydrochloride in 0.1N HCl 
 
8.1.3.2. Determination of absorption maximum in pH 6.8 phosphate buffer:   
                                 The absorption maximum for Venlafaxine Hydrochloride in 
pH6.8 phosphate buffer was found to be 226nm and absorption maximum was shown 
in Figure 8.3  
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Figure 8.3: λ max observed for Venlafaxine Hydrochloride in pH 6.8 phosphate buffer. 
 
8.1.3.3. Preparation of standard graph of Venlafaxine Hydrochloride in 0.1N         
HCl: 
Absorbance was obtained in various concentrations of Venlafaxine 
Hydrochloride in 0.1N HCl were given in Table 8.4 and shown in Figure 8.3. The 
graph of absorbance vs. concentration for Venlafaxine Hydrochloride was found to be 
linear in the concentration range of 4-20 μg /ml. The calibration curve parameters 
shown in Table 8.5. So the drug obeys Beer- Lambert‟s law in the range of                 
4-20 μg/ml. 
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Table 8.4: Concentration and absorbance of Venlafaxine Hydrochloride in 0.1N HCl 
 
S. No Concentration 
(µg/ml) 
Absorbance 
1 0 0.000 
2 4 0.137 
3 8 0.265 
4 12 0.390 
5 16 0.512 
6 20 0.633 
 
 
 
Figure 8.4:  Calibration curve of Venlafaxine Hydrochloride in 0.1N HCl 
Table 8.5:  Calibration parameter values in 0.1 N HCl 
S. No Parameters  Values  
1 Correlation coefficient (r) 0.9997 
2 Slope (m) 0.0315 
3 Intercept (c) 0.0074 
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8.1.3.4. Preparation of standard graph of Venlafaxine Hydrochloride in pH 6.8 
phosphate buffer: 
Absorbance obtained for various concentrations of Venlafaxine Hydrochloride 
in pH 6.8 phosphate buffer were given in Table 8.6 and shown in Figure 8.5. The 
graph of absorbance vs concentration for Venlafaxine Hydrochloride was found to be 
linear in the concentration range of 4–20 μg /ml. The calibration curve parameters 
shown in Table 8.7.So the drug obeys Beer- Lambert‟s law in the range of                  
4–20 μg /ml. 
              Table 8.6:   Concentration and absorbance of Venlafaxine Hydrochloride in 
pH 6.8  phosphate buffer 
S. No Concentration 
(µg/ml) 
Absorbance 
1 0 0.000 
2 4 0.111 
3 8 0.213 
4 12 0.312 
5 16 0.415 
6 20 0.522 
              
 
            Figure 8.5:  Calibration curve of Venlafaxine Hydrochloride in pH 6.8  
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Table 8.7: Calibration parameter values in pH 6.8 phosphate buffer 
 
 
 
 
 
8.1.4.3. Percentage purity of drug 
The percentage purity of drug was calculated by using calibration graph 
method and represented in Table 8.8 
Table 8.8: Percentage purity of Venlafaxine Hydrochloride in pure drug 
  
 
 
 
 
 
The reported percentage purity for Venlafaxine Hydrochloride was 99 to 
102% . 
 
8.1.4. Compatibility testing of drug with polymer: 
  Compatibility of drug and polymers was found to be as following methods 
such as Fourier transform infrared spectroscopy and differential scanning calorimetry. 
 
 
 
S. No Parameters  Values  
1 Correlation coefficient (r) 0.9998 
2 Slope (m) 0.0258 
3 Intercept (c) 0.0035 
S. No. Percentage purity (%) Avg. percentage 
purity (%) 
1 99.98  
100.09 
2 100.12 
3 100.17 
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8.1.4.1. Fourier transform infrared spectroscopy: 
The FTIR spectrums of Venlafaxine Hydrochloride with different polymers 
used in formulation are shown in Figures 8.6, 8.7, 8.8 and Table 8.8.  
            
Figure 8.6: FTIR spectrum of Venlafaxine Hydrochloride with carnauba wax
 
                 Figure 8.7: FTIR spectrum of Venlafaxine Hydrochloride with cetyl 
alcohol 
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Figure 8.8: FTIR spectrum of Venlafaxine Hydrochloride with stearic acid 
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 Table 8.9: FTIR peaks observed for Venlafaxine Hydrochloride  with different 
polymers used in  formulations. 
Functional 
groups 
Peaks observed (wave no. (cm
-1
)) 
Venlafaxine 
hydrochloride 
Venlafaxine 
hydrochloride + 
Carnauba wax 
Venlafaxine 
hydrochloride + 
Cetyl alcohol 
Venlafaxine 
hydrochloride + 
Stearic acid 
C-H 
stretching 
3015.28 3015.19 3015.05 3015.16 
R-O-CH3 
stretching 
2935.16 2919.10 2918.75 2917.73 
NH2 
stretching 
1318.13 1305.56 1317.90 1376.12 
OH stretching 1153.44 1178.73 1153.45 1153.48 
CH2 
stretching 
1042.48 1042.36 1042.06 1042.14 
C-H bending 836.68 836.50 836.68 836.71 
OH bending 740.09 767.47 767.53 767.45 
        
FTIR spectrums were compared, it could indicate that there was no 
incompatibility between drug and polymer. 
According to Table 8.1 and 8.8 and Figures 8.1, 8.6, 8.7 and 8.8, FTIR 
spectrum showed that there was no major difference in peak when compared between 
pure drug of Venlafaxine Hydrochloride  and Venlafaxine Hydrochloride  with 
different polymers. Therefore it could indicate that there was no incompatibility 
between drug and different polymers. 
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8.1.4.2. Differential scanning calorimetry: 
            The compatibility and interactions between drug and best formulation  
polymer were checked using differential scanning calorimetry and the results were 
shown in Figures 8.9 and 8.10 
 
Figure 8.9: DSC thermal analysis of Venlafaxine Hydrochloride 
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                        Figure 8.10: DSC thermal analysis of Venlafaxine Hydrochloride + 
carnauba wax 
 
According to Figures 8.9 and 8.10 and Table 8.10, DSC thermogram showed 
that there was no major difference in onset temperature and peak temperature when 
compared with pure drug thermogram. Therefore it could indicate that there was no 
incompatibility between drug and best formulation polymer. 
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Table 8.10: DSC thermogram parameters of Venlafaxine Hydrochloride with 
Carnauba wax 
S. 
No. 
DSC thermogram  Onset temperature 
(°C) 
Peak temperature 
(°C) 
1 Venlafaxine Hydrochloride 211.56 216.00 
2 Venlafaxine Hydrochloride +  
carnauba wax 
205.90 211.08 
 
According to Figures 8.9 and 8.10 and Table 8.10, DSC thermogram showed 
that there was no major difference in onset temperature and  peak temperature when 
compared with pure drug‟s  thermogram.  No interaction was found between drug and 
polymer.  
 
8.2. Evaluation of granules: 
The granules of different formulations were evaluated for angle of repose, 
loose bulk density, tapped bulk density, compressibility index and Hausner ratio. The 
results of these evaluations were as follows: - 
 
8.2.1. Angle of repose: 
            Angle of repose ranged from 21.31
°
± 0.05 to 23.27
°
± 0.43. The results were 
found to be below 25
o 
and hence the blend was found to have excellent flowability. 
(Table No. 8.10). 
 
 8.2.2. Loose bulk density and tapped bulk density: 
            Bulk and tapped densities are used for the measurement of Compressibility 
index. The LBD and TBD ranged from 0.454 ± 0.00 to 0.476± 0.00 g/ml; and 0.526 ± 
0.00 to 0.555 ± 0.00 g/ml respectively. (Table No. 8.10). 
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                       Table 8.11: Flow characteristics of powder blends 
Formulation 
Code 
Angle of 
repose (
o
)* 
Loose bulk 
density 
(g/ml)* 
Tapped 
bulk density 
(g/ml)* 
Hausner 
ratio* 
Carr’s 
index (%)* 
VF1 22.43±0.02 0.476±0.00 0.555±0.00 1.16±0.01 14.28±0.62 
VF2 21.72±0.01 0.454±0.00 0.526±0.00 1.15±0.00 13.68±0.44 
VF3 23.12±0.03 0.476±0.00 0.555±0.00 1.16±0.01 14.28±0.62 
VF4 22.23±0.06 0.454±0.00 0.526±0.00 1.15±0.00 13.68±0.44 
VF5 21.31±0.05 0.476±0.00 0.555±0.00 1.16±0.00 14.28±0.62 
VF6 22.82±0.12 0.476±0.00 0.555±0.00 1.16±0.00 14.28±0.62 
VF7 23.27±0.43 0.454±0.00 0.526±0.00 1.15±0.00 13.68±0.44 
VF8 22.74±0.39 0.476±0.00 0.555±0.00 1.16±0.00 14.28±0.62 
VF9 23.24±0.51 0.454±0.00 0.526±0.00 1.15±0.01 13.68±0.44 
                      
                       *All the values were expressed as mean± SD, n=3 
 
8.2.3. Compressibility index (Carr’s index): 
 The compressibility index (%) ranged from 13.68 ± 0.44 to 14.28 ± 0.62(Table 
No.8.10). The blend was found to have excellent flowing property as the result were 
found to be below 15%.  
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 8.2.4. Hausner ratio: 
The Hausner ratio ranged from 1.15 ± 0.00 to 1.16± 0.01, (Table No.8.10). 
The result indicates the free flowing properties of the powders. 
 
8.3. Evaluation of sustained release matrix tablets: 
8.3.1. Appearance: 
Surface nature of tablets was observed visually and it was concluded they did 
not show any defects such as capping, chipping and lamination.  
 
8.3.2. Physico-chemical characteristics:  
The physical characteristics of Venlafaxine Hydrochloride matrix tablets (VF1 
to VF9) such as thickness, diameter, hardness, friability, weight variation and drug 
content were determined and the results were shown in table 8.11. 
 
8.3.2.1. Dimension (Thickness and Diameter): 
 The size (diameter) of the tablets was found to be in the range from 
11.15±0.02 to 11.19± 0.02 mm and thickness ranged between 4.44 ± 0.01 to 4.53 ± 
0.01 mm. 
 
8.3.2.2. Tablet hardness:  
 The hardness of tablets was found to be in the range from 6.05± 0.05 kg/cm
2 
to 7.10 ± 0.02 kg/cm
2
. This indicates good mechanical strength of tablet. 
 
8.3.2.3. Percent friability: 
Percentage friability of all the formulations was found to be in the range from 
0.085 to 0.200 %. This indicates good handling property of the prepared matrix tablet. 
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            Table 8.12: Physico-chemical parameters of Venlafaxine Hydrochloride 
matrix tablets  
F. 
Code 
Dimension 
Hardness 
(kg/cm
2
)* 
Friability 
(%)
* 
Weight 
variation 
(mg)
* 
Drug 
content 
(%w/w)*
 
Diameter 
(mm)* 
Thickness 
(mm)* 
VF1 11.16±0.01 4.51±0.01 6.70±0.05 0.114±0.03 350.70±0.75 99.43±0.20 
VF2 11.19±0.01 4.45±0.02 6.15±0.01 0.185±0.01 353.15±1.12 99.39±0.27 
VF3 11.15±0.02 4.53±0.01 7.10±0.02 0.085±0.05 350.81±1.23 99.75±0.11 
VF4 11.17±0.02 4.49±0.01 6.50±0.03 0.142±0.07 351.71±1.24 99.31±0.18 
VF5 11.16±0.01 4.52±0.01 6.85±0.04 0.100±0.03 350.30±1.68 100.01±0.20 
VF6 11.19±0.02 4.44±0.01 6.05±0.05 0.200±0.02 352.86±0.17 99.24±0.41 
VF7 11.18±0.02 4.47±0.02 6.30±0.02 0.171±0.01 352.13±1.50 100.03±0.21 
VF8 11.17±0.01 4.50±0.01 6.65±0.01 0.128±0.09 351.21±0.10 100.38±0.26 
VF9 11.18±0.01 4.48±0.02 6.45±0.03 0.157±0.05 352.10±0.65 99.49±0.24 
                  *All the values were expressed as mean ± SD, n=3. 
 
8.3.2.4. Weight variation: 
A tablet is designed to contain a specific amount of drug. When the average 
weight of the tablet is 400 mg, the pharmacopoeial limit for percentage deviation is ± 
5%. The percentage deviation from average tablet weight for all the tablet was found 
to be within the specified limits and hence all formulations complied with the test for 
weight variation according to the pharmacopoeial specifications IP 2007.  
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8.3.2.5. Drug content: 
 The drug content of all the formulation was found to be in the range from 
99.24± 0.41 to 100.38 ± 0.26 % w/w, which was within the specified limit as per IP 
2007. 
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8.3.3. In vitro dissolution studies: 
Table 8.13: Dissolution profile of formulation VF1 
Time 
(hours) 
Percentage drug 
released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 16.02±0.93 12.02 8.01 0.50 
2 28.63±0.47 21.48 15.17 0.94 
3 39.77±0.72 29.83 21.51 1.38 
4 50.34±0.94 37.76 27.40 1.82 
5 60.21±0.98 45.16 32.98 2.26 
6 72.29±0.95 54.22 38.52 2.80 
7 80.41±0.73 60.31 43.93 3.18 
8 84.41±0.74 63.31 48.74 3.38 
9 86.26±0.73 64.70 52.80 3.49 
10 88.27±1.00 66.21 56.25 3.63 
*All values were expressed as mean ±SD, n=3. 
 
Figure 8.11: In vitro drug release profile of formulation VF1 
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Table 8.14: Dissolution profile of formulation VF2 
Time 
(hours) 
Percentage drug 
released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 14.78±0.71 
11.09 7.39 0.50 
2 27.69±0.47 
20.77 14.32 0.97 
3 35.73±0.92 
26.80 20.12 1.31 
4 43.35±0.47 
32.52 24.97 1.70 
5 51.94±0.92 
38.96 29.51 2.16 
6 62.27±0.71 
46.71 34.11 2.71 
7 76.99±0.71 
57.75 39.19 3.44 
8 84.99±0.46 
63.75 44.41 3.82 
9 87.31±0.93 
65.49 49.05 3.94 
10 90.89±0.70 
68.16 53.05 4.16 
*All values were expressed as mean ±SD, n=3. 
 
Figure 8.12: In vitro drug release profile of formulation VF2 
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  Table 8.15: Dissolution profile of formulation VF3 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0      0.00±0.00 0.00 0.00 0.00 
1 12.31±0.93 
9.23 6.15 0.50 
2 23.04±0.46 
17.29 11.92 0.97 
3 30.13±0.93 
22.60 16.81 1.33 
4 41.43±0.46 
31.07 21.55 1.92 
5 47.68±0.93 
35.77 26.15 2.26 
6 56.76±0.45 
42.57 30.50 2.78 
7 63.10±0.94 
47.33 34.70 3.15 
8 72.72±0.45 
54.54 38.85 3.73 
9 81.47±0.94 
61.10 43.10 4.24 
10 93.04±0.45 
69.78 47.52 4.89 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.13: In vitro drug release profile of formulation VF3 
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Table 8.16: Dissolution profile of formulation VF4 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 17.87±0.93 
13.41 8.94 0.50 
2 31.42±0.92 
23.57 16.79 0.93 
3 49.69±0.46 
37.27 24.72 1.51 
4 57.85±0.46 
43.39 31.98 1.79 
5 71.62±0.93 
53.72 38.53 2.31 
6 74.79±0.46 
56.10 44.31 2.45 
7 78.45±0.93 
58.84 48.93 2.63 
8 81.66±0.46 
61.25 52.82 2.83 
9 82.56±0.93 
61.93 56.07 2.89 
10 83.47±0.45 
62.61 58.77 2.96 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.14: In vitro drug release profile of formulation VF4 
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Table 8.17: Dissolution profile of formulation VF5 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 15.09±0.46 11.32 7.55 0.50 
2 29.24±0.71 21.94 14.86 0.98 
3 38.53±0.93 28.90 21.20 1.35 
4 50.03±0.70 37.52 26.97 1.84 
5 57.57±0.93 43.18 32.34 2.19 
6 60.98±0.71 45.74 36.83 2.38 
7 72.13±0.45 54.10 41.07 3.01 
8 77.32±1.16 57.99 45.28 3.32 
9 82.38±0.71 61.79 49.12 3.63 
10 86.07±1.88 64.56 52.63 3.89 
*All values were expressed as mean ±SD, n=3. 
 
 
              Figure 8.15: In vitro drug release profile of formulation VF5 
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Table 8.18: Dissolution profile of formulation VF6 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 13.39±0.71 12.02 8.01 0.50 
2 26.30±0.92 21.48 15.17 0.94 
3 35.25±0.46 29.83 21.51 1.38 
4 44.73±0.93 37.76 27.40 1.82 
5 51.93±0.46 45.16 32.98 2.26 
6 59.17±0.93 54.22 38.52 2.80 
7 70.16±0.47 60.31 43.93 3.18 
8 75.65±0.94 63.31 48.74 3.38 
9 82.24±0.69 64.70 52.80 3.49 
10 87.33±0.97 66.21 56.25 3.63 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.16: In vitro drug release profile of formulation VF6 
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Table 8.19: Dissolution profile of formulation VF7 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 18.95±0.71 10.04 6.70 0.50 
2 29.42±0.71 19.72 13.27 0.99 
3 37.16±0.94 26.44 19.11 1.37 
4 46.18±0.45 33.55 24.33 1.82 
5 54.31±0.94 38.95 29.13 2.20 
6 63.12±0.69 44.38 33.53 2.60 
7 71.81±0.72 52.63 37.98 3.21 
8 75.45±0.69 56.74 42.35 3.52 
9 80.50±0.70 61.69 46.42 3.92 
10 85.88±0.93 65.50 50.25 4.25 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.17: In vitro drug release profile of formulation VF7 
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Table 8.20: Dissolution profile of formulation VF8 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 15.71±0.71 14.22 9.48 0.50 
2 25.84±0.93 22.07 16.83 0.86 
3 33.56±0.72 27.87 22.32 1.20 
4 41.32±1.18 34.63 27.16 1.65 
5 50.52±0.94 40.74 31.78 2.08 
6 62.55±0.73 47.34 36.27 2.55 
7 77.58±0.49 53.86 40.72 3.03 
8 80.17±0.73 56.59 44.84 3.25 
9 84.78±0.74 60.38 48.52 3.58 
10 86.47±1.44 64.41 51.99 3.95 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.18: In vitro drug release profile of formulation VF8 
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Table 8.21: Dissolution profile of formulation VF9 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 14.93±0.71 11.20 7.47 0.50 
2 23.98±0.46 17.99 13.47 0.88 
3 30.15±0.93 22.61 18.00 1.21 
4 39.75±0.70 29.81 22.24 1.76 
5 47.69±0.47 35.77 26.54 2.22 
6 59.86±0.96 44.90 31.08 2.89 
7 71.17±0.71 53.38 36.00 3.46 
8 77.43±0.46 58.08 40.79 3.79 
9 82.34±0.71 61.76 45.13 4.07 
10 88.50±0.46 66.38 49.16 4.45 
*All values were expressed as mean ±SD, n=3. 
 
                    Figure 8.19: In vitro drug release profile of formulation VF9 
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Figure 8.20: In vitro drug release profile of formulations containing carnauba 
wax polymer. 
 
 
 
             Figure 8.21: In vitro drug release profile of formulations containing cetyl 
alcohol polymer. 
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Figure 8.22: In vitro Drug Release profile of formulations containing stearic 
acid polymer. 
 
 
 
Figure 8.23: In vitro drug release profile for different polymers at 15% 
                                concentration. 
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             Figure 8.24: In vitro drug release profile for different polymers at 30% 
concentration. 
 
 
              Figure 8.25: In vitro drug release profile for different polymers at 45% 
concentration. 
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Figure 8.26: In vitro drug release profile of VF1 to VF9. 
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The drug released from formulation VF4 to VF6 containing cetyl alcohol  at 
three concentration levels of 15%, 30%, 45%  were found to be 86.07± 1.88, 87.33± 
0.97and 85.88± 0.93% for Venlafaxine Hydrochloride respectively at the end of 10 
hours . It was shown in Tables (8.16, 8.17 and 8.18). 
The drug released from formulation VF7 to VF9 containing stearic acid at 
three concentration levels of 15%, 30%, 45%  were found to be 85.88 ± 0.93, 86.47 ± 
1.44 and 88.50± 0.46% for Venlafaxine Hydrochloride respectively at the end of 10 
hours. It was shown in Tables (8.19, 8.20 and 8.21). 
The drug release rate from carnauba wax matrix was found to be high as 
compared to cetyl alcohol and stearic acid; it was shown in Figure 8.22. This might be 
due to slow hydration of matrix and its property to form a thick gel layer, it‟s due to 
slow erosion of matrix and its property which retard the drug release from the tablet 
for long duration.  
 The overall release rate of Venlafaxine Hydrochloride from cetyl alcohol and 
stearic acid matrices are significantly lesser than that from carnauba wax matrices 
were shown in Figure 8.28 and which is confirmed by smaller MDT (2.96, 3.89, 3.63 
and 4.25, 3.95, 4.45) respectively for cetyl alcohol and stearic acid and higher MDT 
for carnauba wax matrices. These results are indicating that carnauba wax has higher 
drug retarding ability for long duration than cetyl alcohol and stearic acid.   
             In addition to concentration of polymer, the type and viscosity of 
polymer also influences drug release. When drug release data obtained from 
dissolution study of different polymers at 15%, 30% and 45% concentration is plotted 
against time (Figures 8.23, 8.24 and 8.25) respectively, it was observed that low 
concentration of polymer induces more drug release. High concentration of polymer 
should be retarding the drug release for longer period of time.  
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                       From the above study, the formulation VF3 was concluded as the best 
formulation among all the nine formulation of this series. Hence the formulation VF3 
was selected for further stability study.   
 
8.3.4. Kinetics of in vitro drug release:  
            In order to investigate the release mechanism, the data were fitted to models 
representing first order, zero order, higuchi and korsmeyer- Peppas. The linear 
regression analysis shown as „r‟ values in Table 8.22, demonstrated that all the 
formulated tablets follows korsmeyer- Peppas release kinetics. The result obtained 
was shown in Figures 8.27 to 8.35. 
 Table 8.22: Different kinetic models for Venlafaxine Hydrochloride matrix 
tablets (VF1 to VF9) 
F. 
Code 
Zero 
order 
First 
order 
Higuchi Korsemeyer- Peppas Best fit 
model 
R
2
 R
2
 R
2
 R
2
 n 
VF1 0.958 0.990 0.975 0.994 0.769 Peppas 
VF2 0.984 0.964 0.960 0.996 0.804 Peppas 
VF3 0.996 0.912 0.948 0.998 0.859 Peppas 
VF4 0.889 0.976 0.980 0.983 0.689 Peppas 
VF5 0.962 0.991 0.981 0.994 0.745 Peppas 
VF6 0.983 0.979 0.969 0.997 0.804 Peppas 
VF7 0.962 0.991 0.983 0.998 0.672 Peppas 
VF8 0.980 0.975 0.959 0.994 0.785 Peppas 
VF9 0.991 0.966 0.953 0.994 0.807 Peppas 
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Figure 8.27: Best fit model (Peppas) of formulation VF1 
 
 
Figure 8.28: Best fit model (Peppas) of formulation VF2 
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Figure 8.29: Best fit model (Peppas) of formulation VF3 
 
 
Figure 8.30: Best fit model (Peppas) of formulation VF4 
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Figure 8.31: Best fit model (Peppas) of formulation VF5 
 
 
 
Figure 8.32: Best fit model (Peppas) of formulation VF6 
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Figure 8.33: Best fit model (Peppas) of formulation VF7 
 
 
 
Figure 8.34: Best fit model (Peppas) of formulation VF8 
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Figure 8.35: Best fit model (Peppas) of formulation VF9 
 
 Further, to understand the drug release mechanism, the data were fitted to 
korsmeyer- Peppas exponent equation, when n < 0.45 indicates fickian drug release. 
For 0.45 < n < 0.89 as anomalous diffusion (non-fickian). In the present study also it 
was observed that almost all the formulated tablets followed anomalous diffusion 
mechanism, which indicates the drug release through diffusion coupled with erosion.   
 
8.4. Stability study: 
After exposure to accelerated stability conditions the formulation was 
analyzed for various evaluation parameters; results were shown in Table 8.23 and 
Figures 8.36, 8.37, 8.38 and 8.39.  
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      Table 8.23: Stability studies of best formulation VF3 (40°C ± 2°C at  75% ±5%) 
Characteristic Initial 1
st
 Month 2
nd
 Month 3
rd
 Month 
Appearance
* Pale yellow No change No change No change 
Hardness (kg/cm
2
)* 7.10±0.02 7.05±0.01 7.00±0.03 6.95±0.01 
Friability (%)* 0.085±0.05 0.083±0.03 0.081±0.01 0.080±0.02 
Drug content (%)* 99.75±0.11 99.61±0.23 99.43±0.10 99.12±0.14 
In vitro drug release at 
the end of 12  hours* 
93.04±0.45 92.86±0.31 92.60±0.27 92.37±0.16 
*All the values were expressed as mean ± SD; n=3 
 
 Figure 8.36 : Comparison for hardness of  before and after stability  
studies of  best formulation VF3. 
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                  Figure 8.37 : Comparison for friability of  before and after stability  
studies of  best formulation VF3. 
 
 
 
 
 
 
 
 
 
 
                     Figure 8.38: Comparisons for drug content of before and after stability 
studies of best formulation VF3.  
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               Figure 8.39: Comparisons for in vitro drug release profile of before  
              and after stability studies of best formulation VF3. 
 
From the above studies there was no significance differences was initiate 
between the evaluated data from initial and after stability studies and all the values 
were found in worth accepting limits. The best formulation was showed           
adequate physical stability at 40
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C ± 2
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C at 75% ± 5% relative humidity.  
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9. SUMMARY AND CONCLUSION 
             
               Oral route has been the commonly adopted and most convenient route for the 
drug delivery. Oral route of administration has been received more attention in the 
pharmaceutical field because of the more flexibility in the designing of dosage form 
than drug delivery design for other routes. The oral route of delivery is perhaps the 
least invasive method of delivering drugs, it‟s a route that the patient understand and 
accepts, patient are able to administer the medicine to themselves. For the 
manufacturer, solid oral dosage form offer many advantages; are generally the most 
stable forms of drugs, are compact and their appearance can be modified to create 
brand identification. 
            Venlafaxine Hydrochloride was chosen as a drug having soluble in intestinal 
pH.  Venlafaxine Hydrochloride plays a major role in treatment of depression. It acts 
as a serotonin-norepinephrine-dopamine reuptake inhibitor. The drug half-life in 
plasma is 5 hours. It is bound to plasma protein about 27%. Venlafaxine 
Hydrochloride is well absorbed with a bioavailability of  45% following oral 
ingestion, hence it was considered as an good candidate for the design of oral 
sustained release dosage form.   
           In the present study, an attempt was made to formulate the oral sustained 
release  matrix tablets of Venlafaxine Hydrochloride to provide a dosage form for 
prolonged period of time, in order to improve efficacy, reduce the frequency of total 
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dose and better patient compliance. Infrared spectroscopy and differential scanning 
calorimetric analysis confirmed the absence of any drug polymer interaction. 
              The sustained release matrix tablets were prepared by Hot melt granulation 
method using different polymers like carnauba wax, cetyl alcohol and stearic acid as 
release retardant polymers. The granules were evaluated for angle of repose, bulk 
density, compressibility index and  hausner‟s  ratio. All the tests revealed that 
granules showed excellent flow properties. 
           The resulting monolithic tablets were evaluated for thickness, diameter, weight 
variation test, hardness, friability and drug content. All the tablet formulations showed 
acceptable pharmacotechnical properties and complied with pharmacopoeial 
standards. The in vitro release profiles from tablets of drug and different polymer ratio 
were applied on various kinetic models. In vitro release studies revealed that the 
release rate was decreased with increase in polymer proportion.  
            In the present studies, matrix formulation VF3 containing Carnauba wax were 
probably showing maximum retardation of drug release and it shows anomalous 
diffusion mechanism, for these reasons, it was considered that the formulation VF3 as 
best formulation among all the nine formulations. Based on release exponent (n) 
values, it was concluded that mechanism of drug release was found to be diffusion 
coupled with erosion (anomalous transport mechanism).  
From the stability studies, there was no significance difference in hardness, 
friability, drug content and in vitro release profile for the best formulation. 
  
 
 
 
     FUTURE  
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10.  FUTURE PROSPECTS 
 
     In the present work, the sustained release matrix tablets of Venlafaxine 
Hydrochloride were prepared by Hot melt granulation technique using carnauba wax, 
cetyl alcohol and stearic acid as release retardant polymers. 
 In this work, only physiochemical characterization such as angle of repose, 
Carr‟s index, hausner ratio, weight variation, hardness, thickness, friability, drug 
content and in vitro evaluation of matrix tablet of Venlafaxine Hydrochloride was 
performed. Along with in vitro studies, in vivo studies of drug  is most important. 
In future in vivo studies are required to set the in vitro - in vivo            
correlation (IVIVC) which is necessary for development of successful         
formulation and also long term stability studies are necessary.
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